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There is a great deal of evidence-based research on ECT, but clearly there is
always much that needs to be researched. Patients present complex problems,
and ECT is itself a complicated treatment. For both of these reasons, these 
guidelines should be considered recommendations rather than requirements,
except when discussing legal mandates. 
Professionals still need to tailor treatments to individual patient needs. Some
latitude is also needed to make certain that professionals practicing in remote
areas are not held to educational standards that are impossible to achieve.
Writers have been asked to use the word “should” when there is a strong belief
that a particular issue must be adhered to. They have used softer words like
“recommend” or “suggest” when they have felt more latitude is warranted.
E L E C T R O C O N V U L S I V E  T H E R A P Y
This report was funded by the Ministry of Health Services and carried out under contract 
with the Mental Health Evaluation and Community Consultation Unit (Mheccu).
All diagrams or charts from journals or other sources are used with the permission of the author.
Limited additional copies of this guide are available through Mheccu, besides digital versions on 
the websites of the Mental Health and Addictions, Ministry of Health Services and Mheccu:
Mental Health Evaluation 
& Community Consultation Unit
2250 Wesbrook Mall
Vancouver, BC  V6T 1W6
http://www.mheccu.ubc.ca/
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I N T RO D U C T I O N
The purpose of these guidelines for electroconvulsive thera-
py (ECT Guidelines) is to standardize the delivery of electrocon-
vulsive therapy services across British Columbia. There will be
differences in the way care is delivered according to local
resources, but good basic care must be available wherever ECT is
provided.
This introduction outlines the responsibilities of various
sectors of the health care system for the delivery of ECT services,
as well as how these guidelines were developed, their scope, and
how they should be applied.
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Responsibility for ECT Services
Responsibility for the delivery of ECT services rests primarily with health care professionals within 
a health authority. However, patients, families, and the Ministry of Health Services also have 
responsibilities, outlined below.
Ministry of Health Services British Columbia
Responsibilities are to
■ Review and revise these guidelines, in consultation with health authorities, professions, and other 
stakeholders, every 5–7 years, depending on developments in the field.
■ Establish in consultation with health authorities, methods of recording data about ECT services that 
make inter-facility comparisons useful for quality assurance purposes.
■ Ensure that accurate information about ECT is made available to the public if public education on 
mental health treatments is provided by or through the Ministry.
Regional Health Authorities
Responsibilities are to
■ Establish clear policies consistent with BC’s ECT Guidelines.
■ Appoint a psychiatrist in each regional health authority to be responsible for the ECT service.
■ Appoint a nurse in each regional health authority to be responsible for ensuring nursing 
procedures are appropriate.
■ Provide equipment and furnishings to make the procedures safe and user-friendly.
■ Ensure staff are appropriately trained, and that there is a program of credentialing to 
administer ECT.
■ Establish and carry out a quality assurance program that may include reviews of privileging, 
equipment, training, patient and family satisfaction, and comparisons with other health 
authorities.
Medical Staff
Responsibilities are to
■ Ensure that there is a functioning privileging system for ECT, and that training and competency 
requirements consistent with these guidelines are established and maintained.
■ Select appropriate patients, provide information to patients and obtain consent from patients 
and involve relatives according to good medical practice. 
■ Liaise with anesthetists, nurses, and other medical specialists as needed.
■ Deliver ECT.
■ Complete records. 
■ Participate in quality assurance activities relevant to ECT services.
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Responsibility for ECT Services, continued
Nursing Staff
Responsibilities are to
■ Ensure that nurses involved with ECT have appropriate training.
■ Prepare patients psychologically and physically for ECT.
■ Participate in the actual delivery of ECT, including preparation and aftercare.
■ Provide education to patients and their families about ECT and the management of the illness 
it is treating.
■ Participate in quality assurance activities relevant to ECT services.
Families and Other Caregivers
Responsibilities are to
■ Support the patient before and after the ECT, by providing care and information.
■ Understand information provided about ECT.
■ Report progress or problems to caregivers if the patient and physician request.
Patients
Responsibilities are to
■ Participate in their care as much as possible.
■ Report positive and negative effects to caregivers.
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Development of the Guidelines
The Ministry of Health Services contracted with the Mental Health Evaluation and Community
Consultation Unit (Mheccu), to write guidelines for ECT in BC. A nine-person advisory committee 
was then created to give overall direction to and review the project. Members included a nurse, a 
representative from the Mood Disorders Association, academic psychiatrists from the University of
British Columbia and the University of Toronto, as well as a clinical psychiatrist from Northern BC, 
and a BC Ministry of Health Services staff member. (See “ECT Guidelines Advisory Committee.”) 
To ensure guidelines were acceptable within the larger hospital community outside of
Vancouver, psychiatric directors at all hospitals with mental health units under the Mental Health
Act were then contacted and asked to share their hospital-specific guidelines, and to participate in
reviewing the first draft. 
Several additional consultations occurred before and after preparation of the first draft. This
included consultations with the Consent Team for the Public Guardian and Trustee Office, the Health
Care Consent and Care Facility Admissions Planning Group, the Mental Health Advocate for BC, the
BC Psychiatric Association Executive, and Registered Nurses Association of B.C. 
Contributing writers reviewed the Canadian Psychiatric Association position paper on ECT, the
American Psychiatric Association’s recommendations for ECT treatment, training and privileging
(2001), and Australian and British guidelines for ECT. The writers also reviewed pertinent literature
for their specific chapters, as well as Mheccu’s ECT literature review.
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Scope of the Guidelines
These guidelines cover patient and family education, clinical applications of ECT by physicians,
nurses, and anesthetists, as well as suggestions for charting, professional education, and quality
assurance programs. 
Chapter 1: “Indications for Use” highlights the dominance of severe depression as the main 
indicator. Other indications such as mania and schizophrenia are also reviewed. Special population
issues such as dementia and pregnancy are also addressed. 
Chapter 2: “Patient Selection and Pre-ECT Evaluation” includes assessments that should be done 
in all cases, and those that may be done according to circumstances.
Chapter 3: “Patient Information and Consent” gives an overview of the laws regarding consent 
in BC for ECT, as well as information considered necessary for providing truly informed consent 
to patients and substitute decision-makers. It provides examples of information for patients 
and families. 
Chapter 4: “Technique, Equipment, and Evaluation” focuses on patient preparation, the use of 
psychotropic medications with ECT, and required equipment. It also discusses the actual application
of ECT, including skin preparation, electrode placement, seizure monitoring, and evaluation of 
individual courses of therapy. 
Chapter 5: “Management of Adverse Effects” reviews the management of major side effects like 
postictal delirium, cognitive changes, and hypomania. It also offers suggestions for professionals 
facing patients who do not appear to be responding to the course of ECT. 
Chapter 6: “Documentation of Individual Courses” outlines the basic pre-treatment and treatment
parameters that need to be documented, illustrated with examples from the BC community. 
Chapter 7: “Continuation and Maintenance ECT” discusses general indications for maintenance 
ECT, the process for administering it, and special considerations in patients who are suffering 
from dementia. 
Chapter 8: “Nursing Considerations” discusses the role of the nurse in both inpatient and outpatient
settings, as well as in the ECT treatment area.
Chapter 9: “Anesthesia Guidelines” reviews requirements for an anesthesic consultation before com-
mencing ECT as needed. It also reviews the procedure used for ECT anesthetic, including the specific
use of medications, and outlines the anesthetist’s role in the post-anesthetic period. 
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Scope of the Guidelines, continued
Chapter 10: “Training and Privileging for Health Care Professionals” discusses guidelines for 
both nurses and physicians. It is recommended that the Head of the Department of Psychiatry 
(or equivalent), should be responsible for appointments, reappointment, monitoring, performance
appraisals, and recommendations for privileging physicians to practice ECT.
Chapter 11: “Quality Assessment,” gives recommendations for quality improvement (QI) activities,
and for maintaining a standard database which should be kept for all patients receiving ECT 
anywhere in the province, in order for individual hospitals to appropriately evaluate their 
performance, and to facilitate inter-hospital comparisons of the provision of ECT.
Chapter 1
I N D I C AT I O N S  F O R  U S E
General Considerations
Electroconvulsive therapy (ECT) is a safe and effective
treatment for a variety of psychiatric and some medical condi-
tions. It has proven superiority in prospective studies compar-
ing ECT with “sham” ECT1,2, and with standard antidepressant
treatment in “medication-resistant” patients.3,4 Especially when
patients are identified early in the course of hospitalization and
offered ECT as a treatment option, there can be a reduction in
the length of stay and hospitalization cost, owing to both effica-
cy and rapidity of response.5,6 There is no evidence to suggest
that ECT response rates (found to be around 75 - 85% for mood
disorders, but as low as 60 - 70% for those resistant to medica-
tion) drops off during the early or late parts of the lifespan. On
the contrary, despite generally higher seizure thresholds in the
elderly, evidence suggests that response rates are higher in both
the “young” elderly (65 - 74),7 and “old” elderly (75 or greater),8,9
with fewer complications compared to certain antidepressants.1
Nevertheless, ECT can induce side effects and may be physically
risky for certain individuals, as is discussed in later chapters.
Relapse rates after an acute course of ECT can be high without
continuation or maintenance pharmaco-therapy and/or ECT.
12 C H A P T E R 1E L E C T R O CO N V U L S I V E T H E R A P Y G U I D E L I N E S
INDICATIONS FOR USEC H A P T E R  I
Primary Indications for Use
As stated in the APA guidelines1, there is “compelling data . . . or strong consensus” supporting
the use of ECT in the following conditions:
Major Depressive Episode (arising from unipolar depression, as part of bipolar
depression, or concomitant manic symptoms during “mixed states”)
ECT should be strongly considered, especially when associated with one of the following features
■ Acute suicidality with high risk of acting out suicidal thoughts.
■ Psychotic features.
■ Rapidly deteriorating physical status due to complications from the depression, 
such as poor oral intake.
■ History of poor response to medications.
■ History of good response to ECT.
■ Patient preference.
■ Risks of standard antidepressant treatment outweigh the risks of ECT, particularly in 
medically frail or elderly patients.
■ Catatonia.
Mania
ECT should be particularly considered if
■ Any of the above features is present.
■ In the presence of extreme and sustained agitation.
■ In the presence of “manic delirium.”
Schizophrenia
According to the APA guidelines1, the following associated features predict a favourable 
response to ECT
■ Positive symptoms with abrupt or recent onset.
■ Catatonia.
■ History of good response to ECT.
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Studies demonstrating a favourable response to ECT in regard to psychotic symptoms have 
generally used a combination of ECT and standard antipsychotics.10,11 There are reports that those
with significant affective symptoms, whether arising from primary schizophrenia12 or schizoaffec-
tive disorder,13,14 can also benefit significantly from ECT. ECT for those with negative symptoms, 
or aggression unrelated to these conditions cannot be advocated at this time because of insufficient
data.
Related conditions such as schizophreniform disorder can also respond favourably to ECT, but
there is insufficient evidence to recommend ECT as being a primary treatment for brief psychotic dis-
order, which by its nature is considered time-limited. However during the course of brief psychotic
disorder, ECT may be an option when the condition is considered life-threatening.
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Primary Indications for Use, continued
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Secondary Indications for Use
Catatonia (unrelated to the primary conditions described above)
There should be a thorough medical and neurological work-up to identify reversible physical 
conditions in order to evaluate the risk for ECT and to initiate prompt medical treatment.
Parkinson’s Disease
The motoric symptoms can improve, especially with associated “on-off ” phenomenon. However, if
an acute course of ECT is initiated, provisions should be considered for maintenance ECT in order to
sustain a remission.15,16 The attending physician should consider adjusting doses of anti-Parkinsonian
agents during the course of ECT due to the possibility of treatment-emergent dyskinesia or psychosis.
Neuroleptic Malignant Syndrome
Antipsychotics should be discontinued and autonomic stability achieved1 before initiating ECT.
Delirium
This should only be rarely considered for patients who require urgent treatment, after medical 
treatment has been initiated to target the specific cause.1 For those who become delirious secondary
to profound physical deterioration (e.g., dehydration) related to the underlying psychiatric disorder 
(e.g., depression), reversible physical factors should be corrected as quickly as possible before ECT 
to lessen risk, but the concomitant persistence of delirium should not necessarily impede the 
consideration of urgent ECT.
Intractable Seizure Disorder
Paradoxically, ECT can be considered when treating status epilepticus that is unresponsive to 
conventional treatments.17
Mood Disorder Secondary to Physical Conditions
Reversible underlying physical conditions should be adequately addressed first, in order to speed 
resolution of symptoms and lessen ECT risks.
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Special Populations
Dementia
The efficacy of ECT when applied to those with dementia and concomitant mood disorder is 
under-studied. Clinical experience, case reports,18 and retrospective case series19 point to ECT being
beneficial in mood, and sometimes cognitive, symptoms and signs in all stages of dementia. There
are also case reports of ECT being successfully used for general agitation20,21 or screaming22,23 related 
to dementia without concomitant depression. However, without further evidence, promoting 
routine use of ECT for dementia without depression cannot be advocated at this time. It is strongly
recommended to consider non-pharmacologic and pharmacologic approaches first.
Aging and dementia increase the likelihood of post-ECT delirium or transient worsening of cognitive
impairment. Adjustment in technique (e.g., switch to unilateral or bifrontal ECT) and/or frequency 
of treatments (e.g., twice weekly instead of thrice weekly ECT) should be optimized to the clinical 
condition during the course, with special attention paid to tracking cognitive status.
Pregnancy and Postpartum Period
ECT is considered a safe and effective treatment in all stages of pregnancy.24,25 Anesthesia consulta-
tion should be obtained well ahead of time because of potential differences in technique, monitoring,
and positioning.1 Obstetrical consultation is also suggested, particularly with high-risk pregnancy
and those near term. Resources should be readily accessible in the event of a neonatal or obstetrical
emergency.1
ECT is also considered a safe and effective treatment in the postpartum period. Anesthetic agents
pose little risk to the nursing infant.1
Children and Adolescents
Sparse data exist on the use of ECT in adolescents, but available evidence suggests that ECT can be
effective for treating the primary conditions outlined earlier (depression, mania, schizophrenia),1, 26, 27,
28, 29, 30 or for catatonia.27 Use of ECT in pre-pubertal children is even more rare, but has been 
successfully applied.27,32
Treating children and adolescents with ECT should be considered only when symptoms are severe, 
persistent, and significantly disabling.31 Other parameters would include life-threatening symptoms
and medication-resistant/intolerant patients.  In the latter condition, since youths often do not
adhere to medication regimes, the adequacy of medication trials needs to be scrutinized before
embarking on a course of ECT.
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Special Populations, continued
Children and Adolescents, continued
A second psychiatric opinion for the necessity of ECT by a clinician experienced in child and 
adolescent issues should be mandatory before proceeding.
Serious complications are rare.27 ECT technique should take into account the younger person’s lower
seizure threshold on average. 
Resource availability, consent, and psychiatric attitudes towards ECT for minors33 are issues 
potentially limiting further study in this area. Nevertheless, ECT can reduce morbidity and mortality
in this age group, just as in other age groups.
Congenital and Acquired Brain Injury
A number of case reports and case series exist describing ECT as being effective in the treatment of 
primary conditions described earlier and catatonia, without promoting persistent cognitive impair-
ment for those with mental retardation34,35 or traumatic brain injury.36 There is a higher risk for 
post-ECT delirium, so adjustments in technique and/or frequency of treatments should be considered.
Cultural Considerations
It is important to understand the cultural context by which patients consent to or refuse ECT. There
may be specific beliefs in certain cultures surrounding electricity and touching of the head that can
prevent patients from accepting ECT as a form of treatment. Another barrier occurs in refugees and
immigrants who may have experienced incarceration for political reasons in psychiatric institutions
and who have been subjected to ECT involuntarily without psychiatric indication. Survivors of tor-
ture who have been subjected to electrical shocks may also resist the notion of ECT. The reluctance 
to proceed with ECT is unfortunate in these circumstances, since these individuals may benefit sig-
nificantly from ECT in treating mood and psychotic disorders that have developed as a complication
of trauma or migration.
Elderly Patients
Aside from physiological considerations during and immediately after anesthesia, being elderly in 
itself confers no specific risk for ECT, and may in fact predict a favourable response when compared
to younger adults. However, being elderly increases the likelihood of dementia and having physical
illness, which may in turn increase the risk for adverse effects due to ECT. For this reason, pre-opera-
tive evaluation is particularly important in the elderly, and an anesthesia consultation is often
appropriate.
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Other Conditions
There are insufficient data to advocate the use of ECT for such conditions as primary anxiety 
disorders, including post-traumatic stress disorder, or primary delusional disorder.37 Those with
chronic pain, along with concurrent affective symptoms, may experience an analgesic effect,38
but this area requires further study. Studies39,40 indicate that those with a personality disorder, 
particularly borderline type, can benefit if they have a concomitant Axis I mood disorder, but there 
is likely a reduced response rate overall, and a higher risk for relapse within one year. Drug-induced
extrapyramidal symptoms have also been reported to improve transiently with ECT, but its role in
this condition has not been firmly established.12
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Chapter 2
PAT I E N T  S E L E C T I O N  A N D  P R E - E C T  E VA LUAT I O N
Selection and Risk
Patient selection is critical in ensuring a high degree of
confidence that ECT will be more effective than other treat-
ments considered, while minimizing risk. Primary and second-
ary indications for ECT, including considerations for special pop-
ulations, has been discussed in Chapter 1. ECT evaluation also
addresses the presence of concurrent medical conditions that
can increase risk, as well as the concurrent use of medical or
psychiatric medications that can alter risk. The risk is defined
as serious morbidity and mortality, which is most likely car-
diopulmonary in nature if occurring,1 and is considered in line
with the risk associated with other low-risk procedures under 
a general anesthetic. While a wide range of mortality rates are
reported in the literature, a widely-quoted figure derived by
Kramer is 2/100,000 individual ECT treatments, yielding a 
figure of 1.6 deaths per 10,000 in a (typical) course of 8 ECTs.2
This approximates the mortality figure of 1/10,000 quoted in 
the APA guidelines.3
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Contraindications for ECT
There are no absolute contraindications for ECT. 
ECT may be deemed necessary even when such “relative contraindications” identified by the APA
guidelines,4 are present
■ Unstable or severe cardiovascular conditions, such as recent myocardial infarction, unstable 
angina, poorly-compensated heart failure, and severe valvular cardiac disease including critical 
aortic stenosis5.
■ Aneurysm or vascular malformation that might be susceptible to rupture with increased 
blood pressure.
■ Increased intracranial pressure, as may occur with some brain tumors or other space-occupying 
cerebral lesions.
■ Recent cerebral infarction.
■ Pulmonary conditions such as severe chronic obstructive pulmonary disease, asthma, 
or pneumonia.
■ Patient status rated as ASA (American Society of Anesthesiologists) level 4 or 5.
Conditions having substantially higher risk with ECT include
■ Pheochromocytoma.
■ Retinal detachment.
■ Acute narrow angle glaucoma.
Those with cardiac pacemakers and implanted automatic defibrillators warrant some caution.
It is unlikely ECT would disrupt the functioning of a modern cardiac pacemaker, but if uncertain, 
consult a cardiologist. The monitoring leads should be well grounded, and it is preferable not to
have someone holding the patient who is grounded to the floor. Implanted automatic defibrillators
are more susceptible to the effects of ECT during stimulation, thus a cardiologist and an anesthetist
should be consulted well ahead of time.
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Pre-ECT Evaluation
Other important concurrent medication should be considered prior to ECT (e.g., atrial fibrilla-
tion, diabetes, hypertension, and gastroesophageal disease), as addressed by the APA guidelines.4 Other 
recent reviews explore ECT in those with cardiovascular conditions,6 those with neurological 
conditions,7 and those who are elderly.8,9
An adequate pre-ECT work-up should include the following, to be carried out within 10 days for 
inpatients or within 30 days for outpatients
■ A physical examination.
■ Evaluation of dentition for the presence of dentures and dental problems that could affect the 
use of the bite-block. Temporal-mandibular joint problems can also be noted.
■ An electrocardiogram for those over age 45, or those with known cardiovascular disease.
Other routine lab investigations are not mandatory and should be guided by the patient’s 
history and a physical exam. Common investigations include hemoglobin, electrolytes, and 
renal function tests.
The pre-ECT evaluation may also include
■ A chest x-ray if there is a florid or unstable cardiopulmonary condition.
■ A cervical spine x-ray in those with suspected cervical spine instability (rheumatoid arthritis, 
severe osteoporosis, Down syndrome, certain collagen vascular diseases) because it would warrant 
full muscle relaxation during ECT and monitoring the maximum relaxation time using a nerve 
stimulator.
■ An anesthesia consult, strongly advised for those over age 60, those with significant cardiovascular
or neurologic conditions, those who are pregnant, and those with potentially unstable cervical 
spine instability.
■ A pertinent specialty consultation (e.g., cardiology, neurology), advised for medical conditions that 
would substantially increase the risk of ECT. Specialty consultation for special populations may also
be indicated (e.g., obstetrics, pediatrics). An obstetrical consult well before the ECT is strongly 
advised for those who have high-risk pregnancies or are near term.
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Pre-ECT Documentation and Referral
The following should be documented before ECT and conveyed to the ECT practitioner
■ Indication for use of ECT.
■ Comorbid psychiatric diagnoses.
■ Concurrent medical conditions, highlighting those that can substantially enhance the risk of ECT
■ Current medications.
■ Whether a physical examination has been done within the recommended time frame, and the 
pertinent findings. A base-line blood pressure and pulse rate should be recorded as part of this 
physical examination.
■ Whether consent was obtained, and who signed the consent (patient, patient’s designated 
substitute decision-maker, public trustee, or medical director).
■ Whether sample information about ECT was given to the patient and/or family.
■ Whether an anesthetist was consulted, and if available, the ASA category.
■ Copies of pertinent consultations by other specialists during the pre-ECT work-up.
■ Whether the patient has a cardiac pacemaker or implanted automatic defibrillator.
■ Dentition and the presence of dentures.
■ Allergies.
■ Base-line cognitive function (MMSE recommended).
■ Any prior history of ECT and its outcome.
■ The referring physician’s or patient’s preference for bilateral or unilateral ECT if requested, and 
a what frequency. However, ECT technique and frequency should be at the discretion of the ECT 
practitioner while considering these preferences and the clinical situation.
■ The name and signature of the attending physician.
Documentation should clearly identify which medications should be held during each ECT 
treatment, which medications should be given on the morning of ECT, and which medications
should be continued post-ECT.
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Chapter 3
PAT I E N T  I N F O R M AT I O N  A N D  CO N S E N T
All patients (and families, or substitute decision-makers
where appropriate) must be given the opportunity to be ade-
quately informed about ECT when it is recommended as a spe-
cific therapy. This chapter sets out guidelines on providing that
information. A valid (informed) consent must be obtained from
voluntary patients using the procedure set out in the Health
Care (Consent) and Care Facility (Admission) Act. Most of the 
Act came into force in February 2000, and affects the provision
of psychiatric and non-psychiatric treatment to adults (includ-
ing those admitted to mental health facilities as voluntary
patients), as well as the provision of non-psychiatric treatment
to involuntary adult patients in mental health facilities. In 
the case of involuntary patients requiring ECT, the process for
obtaining consent is set out in the Mental Health Act and must
be followed. 
Consent should not be viewed as simply filling in a form,
but rather as a dynamic process that starts when the treatment 
is first recommended, and does not end until the therapy is
completed. It should be an interactive educational process
between patients (or their substitute decision- makers), and
mental health professionals, where patients are respected as
individuals with rights and needs, including the right to 
participate in decision-making and treatment planning 
and to have their questions answered.
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The Law: Consent for Voluntary Patients
Under the Health Care (Consent) And Care Facility (Admission) Act1
The attending physician must obtain a valid consent from the patient, including completing
an examination regarding their incapability to consent when there is evidence to support the possi-
bility of incapability. It must be remembered that all patients are to be considered capable unless
there is evidence to the contrary. Other health care professionals (i.e., nurses, psychiatric residents, or
other students) may participate in the process of obtaining a valid consent by giving the required
information to the patient. In the end, however, it is the sole responsibility of the attending physi-
cian (the physician who is overall in charge of the patient’s psychiatric care) to ensure the process is
completed properly. It is the responsibility of the treating physician (the physician doing the ECT) at
the time of the individual treatments to ensure consent forms have been properly signed.
Consent is valid if the following criteria are met
■ The consent that is given is for the health care that is being proposed.
■ The consent is given voluntarily.
■ The consent is not obtained by fraud or misrepresentation.
■ The adult is capable of giving or refusing consent.
■ The health care provider who wants to provide the treatment gives the adult the information a 
reasonable person would require to understand the proposed health care and make a decision 
about it, including information about
• The condition for which the health care is proposed.
• The nature of the proposed health care.
• The risks and benefits of the health care that a reasonable person would expect to be told about,
and any alternative courses of health care, including the option of not receiving the health care.
■ The adult has been given an opportunity to ask questions and receive answers about the 
proposed health care.2
When deciding whether a patient is incapable of making a particular consent decision, a
health care provider must base the decision on whether the patient demonstrates an understanding
of the information given to him or her, and that the information applies to the patient’s own health
situation. Asking the patient to repeat the information in his or her own words or manner is one
way of testing their understanding. Note that the symptoms of a patient’s mental disorder may
impair his or her capability to give a valid consent.
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The Law: Consent for Voluntary Patients, continued
In all situations in which consent is required, the health care professional must consider the
patient’s communication needs and methods, and allow for interpretation or augmentative 
communication strategies when necessary, to ensure the patient has the best opportunity possible 
to understand and participate in decision-making.
If the patient is considered capable, the patient may accept or reject the ECT. If the patient is 
considered incapable of making a health care decision regarding ECT at the time the consent is 
being sought, then a second medical opinion is recommended in all circumstances. A second written
opinion is required if a temporary substitute decision-maker (e.g., the patient's nearest relative) or 
a person named as the patient's representative in a representation agreement made under Section 
7 of the Representation Agreement Act (a basic agreement containing only standard provisions) 
will be making the health care decision.
If the patient is considered incapable of making the health care decision, a substitute decision-
maker must be sought. If the patient has a committee of the person, then the committee should be
asked to make the decision. If the patient has an enhanced representation agreement made under
Section 9 of the Representation Agreement Act, then that representative should be approached for a
decision if he or she is authorized in the agreement to make health care decisions on behalf of the
patient. A representative who is named in a basic agreement (i.e., a Section 7 agreement) and who
has the authority to make health care decisions can make a decision as long as there are two med-
ical opinions.  In addition, if a representative with a “rep 7 agreement,” or a temporary substitute 
decision-maker is making the decision, the Health Care (Consent) and Care Facility (Admission) Act
states that an authorized advocacy organization must be notified (presently the Community Legal
Assistance Society, or CLAS). 
If there is neither a guardian nor a representative (under Sections 7 or 9), in place, a temporary sub-
stitute decision-maker must be chosen from a list of persons prescribed in section 16(1) of the Health
Care Consent and Care Facility (Admission) Act. The health care provider must choose the first of
the following who is available and qualified to act on the patient’s behalf:
■ The patient’s adult spouse (including a common-law spouse or same sex partner).
■ One of the patient’s adult children.
■ One of the patient’s parents.
■ The patient’s adult brother or sister.
■ Any other adult who is related to the patient by birth or adoption. 
A person may not act as a substitute decision-maker for the patient unless they are at least 
19 years of age (i.e., legally an adult in B.C.).  In addition, the person must have been in contact with
the patient during the preceding 12 months, must be capable of making the health care decision,
must be willing to comply with the duties of a decision-maker (e.g., assisting the patient and com-
plying with the patient’s wishes expressed while capable), and must not be in a dispute with the
patient.
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The Law: Consent for Voluntary Patients, continued
Health care providers must not “shop” for substitute consent. The decision made by the substi-
tute decision-maker who is first approached, and who is eligible to make the decision, is the decision 
that must be followed, even if the person refuses to give consent. If the decision is to refuse consent,
the health care provider must not work down the list until he or she finds someone who will give
consent.
If no-one is available or eligible to act as a temporary substitute decision-maker, then the
health care provider must choose a person authorized by the Public Guardian and Trustee’s office
(PGT) (e.g., a friend of the patient, a relative-in-law), or an employee of the PGT.
If the guardian, representative, or temporary substitute decision-maker refuses treatment on
the patient's behalf and a health care professional is concerned about the welfare of the patient
because of this decision, then the health care professional can refer the decision to the Health Care
and Care Facility Review Board. Patients, and all parties entitled to make decision on their behalf,
can also refer decisions to give, refuse, or revoke consent to the Health Care and Care Facility Review
Board.
The temporary substitute decision-maker makes the decision to accept or reject the treatment.
The treatment must start within 21 days from the date on which the substitute makes this decision.
The attending physician must immediately notify an authorized advocacy organization (presently
CLAS), and the adult after the substitute has made the decision to consent to the ECT on the patient’s
behalf. In addition, there must be a 72-hour delay before the treatment is started, to allow the adult,
family member, or advocacy organization to request a Review Board hearing regarding the decision
if they so wish. 
If there is no request for a Review Board hearing, then the treatment may proceed. If there is a
request for a Review Board hearing, the hearing must occur within 7 days. The Health Care and Care
Facility Review Board may confirm the decision under review, or substitute its own decision. The
Review Board’s decision may be appealed to the Supreme Court of BC within 30 days after a decision
is made by the Board, during which time the treatment may not occur unless the court makes an
interim order authorizing treatment to prevent physical or mental harm to the patient. (See
Appendix A for a flowchart reviewing the process of consent for a voluntary patient.) 
It should be remembered that a person holding power of attorney and a committee of the
estate have authority only over a patient's finances. They do not have the authority to make substi-
tute health care decisions. Remember also that representation agreements and committeeships can
involve the management of a patient's property and financial affairs, decisions about their personal
care and health care, or both. Consequently, the health care professional must make certain that the
substitute decision-maker has the necessary authority to make substitute health care decisions. It is
advisable to ask for and to read a copy of the representation agreement or the court order appoint-
ing the committee.
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The Law on Consent for Involuntary Patients: the Mental Health Act
(amendments in force November 15,1999)3
When an adult is admitted to a mental health facility as an involuntary patient, the attending
physician has a responsibility to inform the patient regarding the appropriateness and risks of ECT,
if it is a recommended therapy. If the patient is considered capable of making the health care deci-
sion, then the patient may give or refuse consent and sign the consent form (Form 5: see Appendix
E). If the patient is considered incapable, the attending physician should discuss the case, either in
writing or orally, with the director of the facility, or his or her designate. That person may sign a
Form 5 – a substitute consent – for the involuntary patient. Treatment may not proceed without a
valid consent from the patient or valid substitute consent from a lawful substitute.
The assessment of incapability, under the Mental Health Act involves the attending physician
informing the patient of the nature of their condition, as well as the reasons for and likely conse-
quences of the proposed treatment. To be considered capable of making the health care decision
under the Mental Health Act, the patient must demonstrate that he or she appreciates the nature 
of their condition, the reasons for treatment and its likely consequences.
When an adult is to receive treatment as an involuntary patient under the Mental Health Act,
it may be helpful and appropriate to ask a family member, friend, or other person supportive of the
patient to be involved in the informational process associated with obtaining a valid consent, in
order to assist the patient throughout the course of ECT in understanding the procedures that are 
followed. (See Appendix D for a flowchart reviewing the process of consent for involuntary patients).
The Mental Health Act does not require a second medical opinion. However, it is recommended
that a second medical opinion be obtained wherever possible when a decision to do ECT is first
made, to ensure that the patient receives the most appropriate treatment. 
Section 31 (2) of the Mental Health Act permits a patient, or someone acting on his or her
behalf, to request a second medical opinion regarding the appropriateness of the treatment. A second
medical opinion can be requested once per renewal period (at 1 month, 2 months, 3 months, and
every 6 months thereafter). The second medical opinion is documented on Form 12 (See Appendix F).
The director of the designated facility is required to sign the form to indicate that he or she has
received the report. Following the receipt of the second medical opinion and discussion with the con-
sulting physician, the director must consider whether changes should be made to the patient’s
authorized treatment. It should be noted that if a patient is released on extended leave, psychiatric
treatment authorized by the director is still deemed to be given with the consent of the patient. This
applies to patients receiving maintenance ECT upon discharge. If an involuntary patient on extend-
ed leave requires non-psychiatric treatment, the procedure for obtaining consent or substitute con-
sent is the procedure set out in the Health Care (Consent) and Care Facility (Admission) Act for any
adult who requires health care.
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Repeat or Renewed Consents
Generally patients respond in 6 – 12 treatments for an index course. In certain cases, patients
may require a substantial number of treatments to improve. It is recommended that if a patient does
not show significant response after 15 treatments of an index course, another medical opinion
should be sought at that time regarding the appropriateness of continuing the therapy. In fact, there
is some support for the view that another medical opinion should be considered if the patient shows
no response after a slightly lesser number of treatments. At all times along a course of ECT, it is 
necessary to check repetitively the patient’s (or the substitute decision-maker’s) understanding of 
the rationale for the treatment, and this person’s continuing consent. If after one or more treatments
a voluntary patient refuses to continue or withdraws consent, that position must be accepted. Once
informed consent is withdrawn, a new informed consent must be obtained before continuing. 
It is recommended for maintenance ECT that a renewed consent is obtained after either 6
months or every 15 treatments. This should be established policy by each hospital. 
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Knowledge of Adverse Side Effects
Health care professionals are encouraged to read Chapter 5, “Management of Adverse Effects,” 
in The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and
Privileging (2nd edition), a Task Force Report of the American Psychiatric Association published in
2001. This is a very thorough literature review, with up to date references, and is considered the best
resource on this topic.4
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Giving Information to Patients or 
Substitute Decision-Makers for Consent
A health care professional must directly communicate information orally to the patient and/or
the substitute decision-maker. It is recommended that a standard package of written information be
given to all patients so that they can take it away and look at it privately, at a later time. (See
Appendices G and H.) It may be prudent to have a videotape of ECT information available for the
patient and family to observe. Either a physician or a nurse should answer any patient, family, 
or substitute decision-maker’s questions after they have viewed the video.
Information given to patients and/or their substitute decision-makers should allow them to
make an informed decision. The patients must be told why ECT is being considered for them at this
time. They must be given information about ECT in general, and how the treatment is provided in a 
particular treatment setting, in a way that is sufficiently clear for them to understand given their
educational backgrounds and learning styles. They also must be given sufficient time to think 
about the options and discuss them with their closest friends, relatives, and health care team. 
There are three different types of information that should be given to all patients in proposing 
a recommended course of ECT
■ A standardized general information package about ECT (see Appendix G).
■ A list of recommended ECT information resources, including internet sites, books and videos 
(see Appendix G). 
■ A standardized hospital-specific information package about practical issues surrounding the 
administration of ECT. (See the following section for guidelines.)
PATIENT INFORMATION AND CONSENTC H A P T E R  3
Guidelines for Standard Hospital-Specific Information Packages
Patient information packages individualized for specific hospitals are recommended for giving
practical information about the administration of ECT. Having information with the hospital logo on
it personalizes the treatment for patients, and hospitals may also wish to have very specific guide-
lines for their own patients. These information packages should be written in plain language, in
either 12- or 14-point print. The following is a list of items considered essential for appropriate edu-
cation for patients regarding ECT
■ Usual booking times and days for inpatients, or the place to come and the time to show up for 
outpatients, including the days.
■ Hospital-specific requirements for taking nothing by mouth before ECT
■ Requirements to wear no nail polish, jewelry (except rings), or contact lenses, and not to bring 
contacts or glasses to the treatment suite or OR
■ Instructions regarding the administration of medications the night before and the morning of ECT.
■ Instructions to empty one’s bladder directly before going into the treatment area.
■ The use of preoperative medications.
■ The procedures carried out within the treatment suite or OR, including having an IV started; a 
blood pressure cuff put on; and ECG leads, EEG leads, and the stimulus band applied.
■ The recovery room process, including monitoring of vital signs, as well as the approximate time 
for inpatients and outpatients to recover before going back to their rooms, or being allowed to 
go home.
■ Post-discharge information for outpatients, including requirements to have a responsible person 
drive them home, not to drive or drink any alcohol for 24 hours, and to rest for a specific period on
the day of the ECT.
■ Instructions to patients about speaking to their nurse or their attending physician about any 
questions they may have about the procedure, and the importance of telling the nurse and the 
doctor about all side effects or perceived benefits from the treatments. 
For an example, See Appendix H, Vancouver Hospital’s Patient Information Booklet.
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Consent Forms
It is recommended that general consent forms for procedures within a particular hospital be
used. It is not necessary to develop a specific form for ECT because the important part of informed
consent is the interactive informational process and its documentation.
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Documentation of Informed Consent
It is necessary for all health care professionals involved in the process of obtaining informed
consent to briefly document in the patient’s chart what information has been given, and what the
outcome of the discussions have been regarding acceptance or rejection of the treatment. All of the
patient’s questions must be answered, but not necessarily documented. The fact that the patients
have received written information should also be documented. If patients view videos, this should be
documented as well.
The conclusion of the competency assessment must be documented. If the patient is considered
not competent, the basic reasons for this determination should be given
Contacting the Public Guardian and Trustee
The Health Care Decisions Office is based in Vancouver, and may be reached at (604) 775-0775,
toll free at 1-877-511-4111, by fax at (604) 775-0777. If a health care professional needs more informa-
tion about the process of consent under the Health Care (Consent) and Care Facility (Admission) Act,
this office will be helpful in directing them to the appropriate resource. The Public Guardian and
Trustee Website may also be helpful: www.trustee.bc.ca.
Consent for Patients under Nineteen Years of Age
Changes to the provincial Infants Act (R.S.B.C., 1996, c. 223),5 which came into force in early
1993, removed the minimum age below which a young person or minor (someone under 19, known
as “infant” in legislation) could not give or refuse consent to his or her own health care. Now each
case must be assessed on the basis of the young person’s capacity to understand information being
given to him or her by a health care provider at the time health care is being proposed. This is some-
times referred to as the “mature minor” test. The majority of jurisdictions in Canada have adopted it.
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Consent for Patients under Nineteen Years of Age, continued
Consent can be obtained from a young person only if the health care provider proposing to give 
health care has both
■ Explained to the young person, and is satisfied, that he or she understands the nature, 
consequences, and the reasonably foreseeable benefits and risks of the health care.
■ Made reasonable efforts to determine, and has concluded, that the health care is in the young 
person’s best interests. 
If in the opinion of the health care provider the young person does not understand the informa-
tion being given about the proposed health care, substitute consent must be obtained from the
young person’s parents or legal guardian.
In general, the younger the person is, the more likely it is that parental consent will be
required because the young person lacks the maturity to make his or her own decision. If a young
person who is capable gives consent for the health care provider to inform his or her parents or legal
guardian, this should not be viewed as the equivalent of a parental authorization or consent. If the
young person is capable of making the health care decision, he or she is the only person
who can give (or refuse) consent, regardless of what a parent might say. 
In some cases, health care providers may not be prepared to provide treatment unless parents
are involved and agree with the decision. While this might be good practice, the Infants Act does not
now require it. Young people who are mature enough to make their own health care decisions are
entitled to make those decisions without parental interference,6 provided that the proposed health
care is deemed to be in their best interests.
Section 17 of the Infants Act is the source of the proviso that young persons may consent only
to treatment that is in their “best interests.” This does not include inappropriate or unnecessary
treatment. Generally speaking, “best interests” means that the health care must be given in the
expectation that it will improve (or prevent deterioration or impairment of) the young person's
physical or psychological health. If a health care provider has doubts about whether proposed health
care would be in the young person’s best interests, a second opinion should be obtained. 
Young people under the age of 19 can be admitted involuntarily to a mental health facility
under the Mental Health Act. In these circumstances, the Mental Health Act provides for substitute
consent to psychiatric treatment to be given by the director of the facility following the same pro-
cedure, and using the same form (Form 5: see Appendix E) as for adult involuntary patients. If the
young person requires treatment other than psychiatric treatment, the Infants Act procedure must
be followed. 
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The Mental Health Act provides direction on admitting children and youths, and protects their 
rights by providing for regular reviews and early access to the Review Panel. The Mental Health Act
also provides for young persons under 16 years of age to be admitted to a mental health facility by
their parents or guardian as voluntary patients if the admitting physician and director agree. Once
a minor under 16 years of age is admitted on this voluntary basis, only psychiatric treatment
may be given with the consent of the parents or guardian. If he/she requires non-psychiatric 
treatment, the Infants Act procedure must be followed.
Form 1, Request for Admission (Voluntary Patient) (see Appendix B), and Form 2, Consent for
Treatment, (Voluntary Patient) (see Appendix C), must be filled out by the parent or guardian 
admitting a young person.
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List of Chapter 3 Appendices
Appendix A:
Consent in Major Health Care for Incapable Adults for Voluntary Patients – this has been amended
for ECT. The original document is in the educational package created by the Public Guardian and
Trustee’s Office for Acute Care Consent.
Appendix B:
This is Form 1 of the British Columbia Mental Health Act 1996, which in that document is 
in Appendix D.
Appendix C:
This is Form 2 of the British Columbia Mental Health Act 1996, which in that document is 
in Appendix D.
Appendix D:
ECT Treatment Consent for Involuntary Patients – this algorithm was created for this document 
by Dr. M.L. Donnelly and Dr. John Gray.
Appendix E:
This is Form 5 of the British Columbia Mental Health Act 1996, which in that document is in
Appendix D.
Appendix F:
This is Form 12 of the British Columbia Mental Health Act 1996, which in that document is 
in Appendix D.
Appendix G:
Standard General Information Package General Information about Electroconvulsive Therapy (ECT).
This was created for this document by Dr. M.L. Donnelly. This document can be photocopied and used
in any way that is helpful.
Appendix H:
Electro-Convulsive Therapy (ECT) Information Booklet. This patient and family information booklet
was created by Psychiatry Nursing and Education Services, University Hospital, Vancouver, revised
by Marg Acton, Educator and Jeanette Eyre, ECT Coordinator UBC Hospital. Permission has been
granted for this document to be used as is seen helpful, as long as the original development by
Vancouver’s University Hospital is cited in its use. 
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CONSENT IN MAJOR HEALTH CARE FOR INCAPABLE ADULTS FOR VOLUNTARY
PATIENTS
HCP proposes major health care
HCP forms opinion re:
capability/incapability
Acute capable –
adult’s decision followed
Adult Incapable
Second Medical Opinion
Confirm whether representative,
or committee of person exists
If representative/committee
is available –
follow that patient’s decisions
If none exists or is not available:
HCP determines which family
member is available and qualifies
to be chosen as TSDM
HCP chooses a TSDM, or
If TSDM unavailable or
unqualified,
request Public Guardian and
Trustee to authorize a TSDM
TSDM makes decision
HCP notifies adult and others, using
Form 1, of:
- need for health care and incapability
- name of TSDM and health care decision
- right to request review within 72 hours
HCP notifies
CLAS if a TSDM
or REP 7 makes the
decision
no review requested
within 72 hours
TSDM decision followed
(Consent) (Refuse/revoke)
Health care provided
after 72 hrs
(but within 21 days)
Health care
not provided
R
ev
ie
w
 B
oa
rd
 P
ro
ce
ss
If review requested
(within 72 hrs)
Board Hearing
(to be held within 7 days)
Board Decision
Health Care
(Consent to) (Refused)
Health care
provided
(no 21 days
time limit)
Health care
not provided
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ECT TREATMENT CONSENT FOR INVOLUNTARY PATIENTS
        
Note:  A 2nd medical opinion may be requested by the patient, or substitute decision-maker once
per renewal period, regarding appropriateness of ECT as a therapy.
ECT recommended for an involuntary
patient
Competency assessment
by attending physician
Documented process of informed
consent by attending physician
  Patient capable
   Patient agrees to treatment and signs Form 5
     Patient incapable
Attending physician
discusses with director
or designate and
arranges a second
medical opinion
regarding ECT when
required, or whenever
possible
Director or designate signs
Form 5
Treatment proceeds
    Treatment Proceeds
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Standard General Information Package
General Information about Electroconvulsive Therapy (ECT)
What is ECT?
Electroconvulsive therapy (ECT) is a physical therapy in which a patient under general anesthetic
will have an electrical current passed through his or her brain, causing a seizure in the brain. This
therapy was developed in the 1930s and has become a painless, safe, effective therapy for a number
of psychiatric problems. 
How does it work?
Current theories suggest that the seizure activity causes changes in brain chemistry.
When is ECT used?
ECT is used primarily for depressive illnesses. It is usually reserved for situations where medications
have not worked, but it may be the first choice of therapy for frailer, older patients for whom 
medications may be more of a problem. If a patient has responded well to ECT in the past, it may 
be his or her own first choice. ECT is also used occasionally in mania, schizophrenia, and in severe
Parkinson’s disease.
How is the procedure carried out?
Patients are treated in specific ECT suites or in hospital operating rooms. You will be given an 
intravenous line. Sensors monitoring your heart and brain waves will then be applied to your head,
and you will be given a short-acting general anesthetic. Once you are asleep, you will be given a
muscle relaxant. When you are completely asleep and your muscles are relaxed, a brief electrical
current will applied to your brain either unilaterally (on one side), or bilaterally (on both sides). A
brief seizure will follow, which will be modified by the muscle-relaxants so that medical staff may
need to look carefully at brain wave monitors and observe your toe and hand movements to 
monitor it. The whole procedure takes only a few minutes. You will then be moved to a recovery
area where a nurse will closely observe your pulse and blood pressure until you are awake enough 
to return to your room or to the outpatient clinic.
How many treatments are required?
Usually patients with acute psychiatric problems require 6 – 12 treatments, given either 2 or 3 times
a week. Occasionally more treatments will be required for maximum benefit. 
In order to keep patients well, outpatient maintenance ECT is sometimes recommended. In such
cases the treating physician determines the number and frequency of treatments by assessing 
specific clinical problems and needs.
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Standard General Information Package, continued
General Information about Electroconvulsive Therapy (ECT), continued
What are the benefits of ECT?
ECT has produced substantial improvement in most of the patients who have been treated with it. It
has been shown to be effective in many who have not responded to other forms of treatment. In fact,
between 50 – 70% of patients who previously did not respond to medications will respond positively
to ECT.1 Many depressed patients have problems with their memory; after their depression is relieved,
which may occur after having ECT, their memory may improve. 
Improvement is gradual over several treatments until most or all symptoms of a depression are
relieved. You may notice an improvement of appetite early on, later an improvement in energy, and
finally an overall sense of feeling better. The treatment team will work with you to monitor your
individual symptoms and response. 
What are the side effects?
Immediately after ECT, you may experience some nausea, headache, and muscle aches. These are
most often managed by taking plain Tylenol tablets. You may experience some acute confusion on
the day of the ECT treatment, which most often resolves quickly. You may also forget recent events or
events occurring around the time that you have the ECT. These memory problems are usually minor
and may be decreased by slight changes in the procedure. Some patients experience longer-lasting
problems with recalling memories from around the time of the ECT, and occasionally problems recall-
ing some distant events. These memory effects generally subside once the ECT is completed. A few
patients may have more severe problems remembering events from the distant past. Patients gener-
ally have fewer memory problems with unilateral ECT compared to bilateral ECT. Your treating 
psychiatrist will further explain this.
You should always report possible side effects to your nurses or psychiatrist, so the treatment team
can work to reduce them. 
ECT is considered very safe, and no more dangerous than a minor surgical procedure requiring a
short general anesthetic. A current estimate of mortality in ECT is 2 in every 100,000 treatments.2 If
you are worried about this, please discuss it with your psychiatrist.
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Standard General Information Package, continued
General Information about Electroconvulsive Therapy (ECT),
continued
How do I give consent, and what are my rights to withdraw consent?
Your treating physician will inform you about the reasons ECT is being considered as an appropriate
therapy for you. You will also be informed about possible alternative treatments and will get the
opportunity to ask questions about your proposed treatment. Your treating physician will request
your informed consent by asking you to sign a consent form.
In circumstances where voluntary patients are not able to give their own consent, the physician 
will seek consent from a substitute decision-maker, in this order: their adult spouse, one of their
adult children, one of their parents, one of their adult brothers or sisters, or any other adult related
to them by birth or adoption. For involuntary patients, the medical director may be asked to 
give substitute consent. A second med Iical opinion can be requested about appropriateness of 
the treatment.
You or your substitute decision-maker may withdraw consent even after the treatments have 
started. The treating psychiatrist will arrange for appropriate alternative treatments.
What happens after ECT?
Your physician will discuss what treatments are suggested to keep you well after ECT has been 
completed. In most circumstances they will suggest the follow-up use of medications. In some 
situations, they may recommend a course of maintenance ECT to maintain improvement.
How can I find out more about ECT?
You can find out more about ECT by checking the following resources:
Internet sites
■ The Royal College of Psychiatrists http://www.rcpsych.ac.uk/info/webguide/ect.htm
■ The American Psychiatric Association http://www.psych.org/public_info/ECT~1.cfm
■ American Academy of Family Physicians http://familydoctor.org/handouts/058.html
■ The Mayo Clinic http://www.MayoClinic.com/home?id=HQ00612
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Standard General Information Package, continued
Books
■ Electroshock: Restoring the Mind, by Max Fink. New York: Oxford University Press, 1999.
Riverview Hospital Library Call no. WM/412/F56/1999
■ Holiday of Darkness by Norman S. Endler (revised edition). Toronto: Wall and Thompson, 1990
Videos (available at Riverview Hospital Library)
■ Electroconvulsive Therapy: ECT: The Treatment, The Questions, The Answers by Leon Grunhaus, 
Lisa Barroso-Whal. Ann Arbor, Mich: University of Michigan, 1988.  Call number: 
WM/412/G78/1988
■ Electroconvulsive Therapy: Information for Patients and their Families by American Medical 
Communications. American Medical Communications, 1997  Call number: WM/41/E53/1997
■ Informed ECT for Patients and Families, with Dr. Max Fink by Max Fink (15 min.). Lake Bluff, 
Ill.: Somatics, 1986.  Call number: WM/412/I53/1986
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Chapter 4
T E C H N I Q U E, E Q U I P M E N T, A N D  E VA LUAT I O N
Setting
ECT can be provided in a variety of settings. For centres
where ECT is provided for a large number of patients, a desig-
nated suite housing a receiving/waiting area, the procedure
room, and a post-ECT recovery area for close patient observation
would be ideal.
Alternatively, ECT is also commonly offered in pre-opera-
tive hospital holding areas, or within an operating room itself.
Essential elements to any site include the provision of privacy
for the patient receiving ECT, and adequate space for the anaes-
thetic and ECT equipment, as well as for staff to assist with the
procedure. ECT should be carried out close to the necessary
resources in case of a medical emergency.
In addition to the post-ECT room, patients undergoing 
outpatient ECT should have access to a supervised day room
(i.e., the lounge of an inpatient psychiatric ward), where they
can rest, read, or eat until they are ready to be discharged.
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Patient Preparation
The patient should
■ Have their initial weight recorded on the ECT Checklist.
■ Be NPO. (See Chapter 9, “Anesthesia Guidelines,” on oral intake.)
■ Remove jewellery, hair accessories, contact lens, glasses, hearing aids, and dentures. Local policy 
can state whether glasses or dentures can be kept for transport.
■ Receive pre-ECT medications (if ordered) and most routine a.m. medications 1 hour before ECT, 
with sips of water if oral. 
■ Void his or her bladder and bowels.
■ Be wearing an incontinence pad if he or she has bladder or bowel instability.
■ Have pre-ECT vital signs and, if diabetic, blood sugars recorded on the chart before each treatment.
■ Have clean hair if at all possible.
The physician should be alerted to any change in medication and patient status if notable 
since the last treatment.
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Psychotropic Medications during ECT
A careful review of medication is essential before starting a course of ECT. Existing medications
for medical illness can usually be continued throughout the ECT course and given one hour before
the ECT with sips of water, or after the treatment when the patient is fully awake. Diabetic patients
should be given priority if several patients receive ECT on the same day. Insulin and hypoglycemic
agents are usually given after the treatment. Medical consultations may be requested for patients
with poorly-controlled blood sugars or with respiratory or cardiovascular illnesses.  
Consideration should also be given whether to continue psychotropic medications throughout
an ECT course. As a general rule, it is favourable to discontinue as many medications as possible to
decrease the risk of delirium and minimize cognitive side effects. This is particularly applicable to
those bearing anticholinergic effects.
On the other hand, in bipolar patients, it may be necessary to maintain mood stabilizers
throughout the ECT course; for example, to reduce the risk of iatrogenically shifting a patient’s
depressed state into mania.
No substantial evidence currently exists to support that the combined use of ECT and medica-
tions improves the efficacy of ECT in symptom reduction.
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Psychotropic Medications during ECT, continued
Antidepressant Medications
■ Selective Serotonin Reuptake Inhibitors (SSRIs)
SSRIs are commonly administered throughout the ECT course. Conflicting reports exist about the 
safety of this; some point towards a possible improved result when combined with ECT, some report 
no improved results, and others suggest both shortened seizure length and prolonged seizure length.
Discontinuing SSRIs before ECT may be recommended for patients at higher risk of post-ECT delirium
(i.e., those on multiple medications, the elderly, or those with co-existent dementia). If SSRIs are con-
tinued, the anesthetist should be informed and alerted to the possible risk of a prolonged seizure.
■ Monoamine Oxidase Inhibitors (MAOIs)
Selective MAOIs (e.g., moclobemide) are likely safe to continue, although little data exists 
on their effects.
Nonselective MAOIs (e.g., phenelzine, tranylcypromine) are also likely safe to continue. If hypotension
occurs during the ECT, indirect-acting vasopressors should be avoided and neosynephrine used
instead. In such a circumstance, an anesthesia consultation should be done before the first ECT.
■ Tricyclic Antidepressants (TCAs)
These are likely safe to continue. TCAs with stronger anticholinergic side effects (e.g., amitriptyline,
imipramine, trimipramine, clomipramine) have increased risk of creating post-ECT confusion, and
should be discontinued if possible.
■ Bupropion Hydrochloride
No data exists about the safety of bupropion (Wellbutrin) during ECT. Due to case reports of 
spontaneous seizures, it should likely be discontinued.
■ Others (e.g., Venlafaxine, Nefazodone, Trazodone)
No data exists.
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Psychotropic Medications during ECT, continued
Mood Stabilizers
■ Lithium Carbonate
Controversy about the use of lithium during ECT centres on reports of increased risk for delirium, 
prolonged seizures, and possible decreased seizure thresholds. Generally lithium is well-tolerated 
at lower doses, and may have to be continued in patients with refractory mood disorders. Lithium
should be held the night before and the morning of ECT and given post-ECT. Lithium carbonate 
levels should be done before ECT.
■ Anticonvulsant Agents (Carbamazepine, Valproic Acid, Gabapentin, Lamotrigine,
Phenytoin, Topiramate)
Again, clear guidelines do not exist, but reports point towards decreased seizure time, higher seizure
thresholds, and possible decreased efficacy of ECT for improving mood symptom when they are used
concomitantly with ECT. They are generally well tolerated, however. If they are being used as mood
stabilizers, doses should be held the night before and the morning of ECT.
■ Antipsychotic Agents
Traditional antipsychotics lower seizure threshold, but as with TCAs, may increase post-ECT delirium
if they hold a stronger anticholinergic profile (e.g., chlorpromazine, thioridazine, methotrimeprazine,
and fluphenazine).
Little information exists about the safety or efficacy of combining ECT with novel antipsychotics.
Reserpine has been associated with death when used during ECT and should therefore not be used.
■ Benzodiazepines
Benzodiazepines are commonly used in a variety of psychiatric illnesses, and have a major effect on
ECT. They clearly increase seizure threshold. Many reports also define their role in lessening seizure
efficacy for mood symptoms. If the indications for benzodiazepine use cannot be managed by other
substitute agents (e.g., sedatives, antipsychotic agents), then
■ Benzodiazepines with medium half-life (i.e. 8 hours) should be used, and held the morning 
of ECT.
■ IV Flumazenil can be used in the treatment room if it is clear the benzodiazepine impacts 
upon ECT efficacy. IV Midazolam should then be given in the PAR room to ensure withdrawal 
symptoms do not occur.
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Equipment
ECT Devices
Initial models of ECT devices (such as Med Craft) provided a sine wave stimulus. Advancing
knowledge about the effects of different waveforms in ECT has resulted in the development of brief
pulse devices. These offer an equally sufficient stimulus, but with notably less cognitive side effects.
Given this key finding, brief pulse devices have become readily available and are in widespread use.
(See the following chart.) Sine wave machines are no longer acceptable for modern ECT delivery. 
ECT Equipment
■ Brief pulse ECT machine and backup: brief pulse and constant current with wide output range.
■ Electrodes: flat and concave for unilateral placement.
■ Patient stimulus cable, +/- hand-held paddles.
■ EEG cable.
■ EEG disposable electrode pads.
■ EEG recording paper.
■ Adjustable headband.
■ Bite-blocks.
■ Tube of electrode gel.
■ Jar of abrasive conductant gel.
■ Alcohol (for cleaning skin).
■ 2 x 2-inch gauze (for cleaning skin).
■ Bottle of buffered bleach (for cleaning equipment in MRSA-positive patients).
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MECTA Spectrum  0.5–2.0 msc 30–70 hz 0.5–6 sec 500–800 mA 576 mC
Corporation 4000Q 
or 5000Q
Somatics Thymatron 0.25–1.4 msc 10–70 hz 0.14–8 sec 900 mA 504 mC
Incorporated System IV
Bi-Directional Brief Pulse Square Wave ECT Devices (North American Suppliers)
Supplier Model Pulse Width Frequency Duration Current Maximum Charge
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Skin Preparation
For electrical current from an ECT device to reach the brain, it must flow between two metallic 
electrodes. Since blood is a conductor, the brain’s vascular system carries the current. Skin inherently
resists electrical current, so careful site preparation is a key component in ECT delivery. Inadequate
cleansing or sloppy use of conductant gel can result in an inadequate or aborted seizure, and in skin
burns. Skin or scalp preparation involves
■ Thoroughly cleansing the chosen electrode sites with alcohol-soaked gauze squares to remove oil, 
makeup, gel from previous treatments, hair sprays, dead skin cells, etc. Note that shaving the hair
is not required. If a parietal site is used for unilateral ECT, hair can be parted and cleaned as 
described.
■ Massaging an abrasive conductive such as that used in EEG labs into the skin with fingertips, 
in a circular motion.
■ Removing the abrasive gel with a cloth or dry gauze (not with alcohol), to create a dry, clean, 
mildly-abraded area.
■ Applying a conductive ECT gel (non abrasive), onto the electrode surfaces.
■ Firmly pressing the electrodes against the skull, which is imperative to minimize impedance.
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Electrode Placement
Electrode placement continues to be controversial and under active research and debate. It is
generally accepted that bilateral placement is somewhat more effective than unilateral placement,
but that the latter creates less cognitive side effects. Of interest is the emergence in the past few
years of new electrode sites. Treating physicians should follow changing recommendations as they
develop, and familiarize themselves with the benefits and detriments of the various options.
■ Unilateral Placement
The d’Elia position has become the recommended electrode placement site for unilateral, 
non-dominant hemispheric ECT:
Figure 1: The midpoint of electrode one is placed one inch above the midpoint on an imaginary line drawn between the
external canthus of the eye, and the tragus of the ear (i.e., the bottom  edge of a two-inch  electrode is on the line). The
second electrode  is  similarly  placed  one  inch  on  the  right-hand side of two imaginary intersecting  lines;  the  first
drawn  between  the  two tragi of the ears; the second connecting sagittally the inion with the nasion.
(From The Practice of Electroconvulsive Therapy, 2nd ed., p. 1541.) www.appi.org Used with permission.
■ Bilateral Placement (Bitemporal)
The most widely used bilateral electrode placement has been bitemperofrontal. Electrodes are placed
over both temples, as in Figure 1, Position 1, bilaterally.
75 C H A P T E R 4E L E C T R O CO N V U L S I V E T H E R A P Y G U I D E L I N E S
TECHNIQUE, EQUIPMENT, AND EVALUATIONC H A P T E R  4
Electrode Placement, continued
Other Positions
■ Bifrontal Placement
Bifrontal placement with electrodes close together appears to result in less clinical efficacy than the
bitemperofrontal placements, albeit with less cognitive effects. Recent studies suggest two other
bilateral strategies with wider bifrontal placements. The first is described in an original article, J.S.
Lawson.2 Alternatively, a Left Anterior Right Frontal position – the so-called “LART” is introduced by
Schwarz.3 Early work indicates that effective ECT may be deliverable closer to seizure threshold with
bifrontal placement than with either bilatemporal or unilateral positioning.
■ LART (Left Anterior Right Frontal) Placement
The rationale for this electrode site option is that the left anterior electrode lies near the medial
region of the frontal lobes, which is thought to be the cortical region most sensitive to seizure induc-
tion by electricity. It is also believed that one of the reasons these last two positions are more effi-
cient in transmitting current is that these placements avoid skull sutures, and thereby avoid the
concentration of electrical current as it enters the brain. 
The end result is fewer cognitive side effects.
Stimulus Dose Strategies
Since the late 1980s, it has become apparent that the degree to which the electrical dose lies
above seizure threshold has an impact on the efficacy of ECT. A stimulus delivered barely above
seizure threshold can create a grand mal seizure, which will have little effect on improving target
symptoms (i.e., depression). A stimulus that is markedly suprathreshold improves symptomatology,
but also carries with it unnecessary cognitive side effects, causing patient suffering and a prolonged
hospital stay. 
From this have arisen differing approaches to dosing strategy. The “titration method” involves
initially stimulating a patient with a very low electrical dose in “search” of threshold. Gradual dose
increases are then delivered until an adequate seizure is obtained. “Adequacy” is determined via EEG
morphology from the EEG readout delivered by the ECT device. From then on, the electrical dose for
subsequent treatments is either maintained or gradually increased, using EEG criteria as well as
clinical response as a guide. (See the following section, “Seizure Monitoring.”) 
Inherent to this method is the finding that seizure threshold varies from patient to patient.
Concern exists that if all patients – regardless of age, gender, diagnosis, medications, or number of
previous ECT treatments – received the same dose, with the same electrode placement, some
patients (for example, those with high seizure thresholds) will receive sub-optimal treatments.
Others with low thresholds will be left with excessive cognitive effects. Various protocols are avail-
able for the titration method dose scheduling. These are described by Beyer et al.6
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Stimulus Dose Strategies, continued
Another approach uses a formula to guide dosage using the patient’s age. Starting treatments
with half the patient’s age is recommended.4 For example, if a patient is 60 years old, ECT is initiated
at 30% of the maximum output deliverable by the device, then gradually the dose is increased as the
ECT course progresses. Starting ECT at three-quarters of the patient’s age is also possible. 
Finally, some practitioners offer high, fixed-dose, right unilateral ECT for all patients. 
Unresolved, and under active research, remains the effect of individual pulse morphology, which
can be altered on some devices (MECTA SR II, JR II, Spectrum 5000Q, and Thymatron System IV).
Figure 4: Brief Pulse Wave Form (From The Practice of Electroconvulsive Therapy, 2nd ed., p. 1401.) www.appi.org
Used with permission.
Shortened pulse width (0.5 msec or less) and longer pulse trains have now been linked with
increased efficacy in research studies.
Debate also continues on the optimal dose of electricity above seizure threshold. Previously, 2.5
times threshold was considered adequate for unilateral ECT. Some authors5 recommend 5 to 6 times 
threshold. However, this is technically not viable for many practitioners, given the maximum 
output deliverable by current devices; 1.5 to 2.5 times threshold for bilateral ECT (frontotemporal
placement) is generally accepted.
77 C H A P T E R 4E L E C T R O CO N V U L S I V E T H E R A P Y G U I D E L I N E S
TECHNIQUE, EQUIPMENT, AND EVALUATIONC H A P T E R  4
Seizure Monitoring
Central to the delivery of safe and effective ECT is the assurance that
■ A seizure has indeed occurred.
■ The seizure is generalized to both hemispheres.
■ The seizure is of adequate intensity to actually bring about symptom recovery.
■ Unnecessary cognitive side effects are avoided.
Several parameters are observed to help with these clinical judgements:
EEG Activity
It was previously believed that seizure length in ECT reflected seizure adequacy; it was thought a
seizure should be at least 25 seconds long in order to be effective. It is now clear that seizure time is
less important than seizure intensity. Although many factors can affect seizure expression, current
evidence suggests that the following are associated with better clinical outcomes
■ Higher amplitude spike and wave activity.
■ Sharp post-ictal suppression.  (Numbers correspond to those in Figure 5 below.)
Figure 5: EEG Activity associated with better clinical outcomes. Used with permission of Dr. C. Gosselin
The current recommendations for EEG electrode placement sites are minimally one-channel (left side
for right-unilateral ECT), but preferably two-channel frontal mastoid placement
■ At the frontal site, 1 to 3 inches above the eyebrow on the mid pupillary line.
■ At the mastoid site, over the hair-free mastoid bone, directly behind the ear.
Skin should be cleaned with alcohol, dried, +/– use of an abrasive gel for optimum recording.
Pediatric disposable ECG electrodes work well.
Ictal motor activity (optional)
The motor component of a seizure can be monitored using the cuff method. The distal portion of a
limb (preferably the ankle) can be blocked from receiving muscle relaxant by inflating a blood 
pressure cuff above the ankle to a pressure 100 mm Hg above the systolic pressure before ECT 
(i.e., 250 mm Hg). The cuff should be placed on the same side of the electrodes for unilateral ECT to
ensure generalization. This technique is performed before the delivery of the muscle relaxant. The
cuff should be deflated immediately following the seizure to avoid ischemia.
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Seizure Monitoring, continued
The benefit of this method is evidence of a generalized seizure in the event of a faulty EEG.
Limitations are that
■ Tonic/clonic seizure activity stops before seizure activity ceases in the brain, i.e., motor component
timing is not useful in measuring the true total seizure time.
■ This technique is not appropriate for patients with skin or some musculoskeletal diseases such as 
severe osteoporosis, deep vein thrombosis, and sickle cell disease.
Cardiovascular Response
ECT affects the brain and the cardiovascular system. With the initial parasympathetic and
then sympathetic outpouring that results from the seizure itself, brief but impressive falls and rises
in blood pressure and heart rate occur. Continuous ECG monitoring as well as repeated blood pres-
sures and oximetry before, during, and after the procedure are of vital importance.
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Missed or Aborted Seizures
After a stimulus in ECT, it is possible that no seizure is elicited, or that a brief response (less than 15
seconds) results. It is unlikely that most patients can expect to benefit from a seizure of this short
duration, although it is described that some inherently undergo brief seizures (e.g., 17 sec.), with
nevertheless clear and progressive recovery. Possible causes of missed or aborted seizures are
■ Excessive impedance from poor skin contact.
■ Hypercarbia from inadequate ventilation.
■ Hypoxia.
■ Dehydration.
■ Medications (typically benzodiazepines and anticonvulsants).
■ Insufficient stimulus.
Possible remedies for missed or aborted seizures are to 
■ Review the “dynamic impedance” reading, which is elicited by the ECT device. If it is too high, 
examine and correct skin preparation, gel application, and/or electrode positioning.
■ If not too high, restimulate at 50 – 100% above the original dose:
• If a seizure is missed, wait 20 seconds before restimulating to ensure a delayed response 
will not occur (rare).
• If a seizure is aborted, wait 45 seconds before restimulating to overcome the refractory period.
• A third stimulus under the same anesthetic may be tried at a higher dose still, after another 
45–second time lapse, and after it is ensured that no additional anesthetic and muscle relaxant 
needs to be given. 
■ Review the other factors above, such as correct hydration and electrolyte balance. Oxygenate 
adequately and ventilate vigorously prior to the next stimulus. If possible reduce or discontinue 
medications that may hinder the ECT, Flumazenil 0.5 to 1.0 mg iv can be used during the 
anesthetic for patients receiving high-dose benzodiazepines that cannot be altered. This can 
be followed by IV midazolam administration in the PAR to avoid withdrawal symptoms.
■ Note that caffeine sodium benzoate, 500 to 2000 mg iv (or orally one-hour pre ECT with sips 
of water), can lengthen seizure time.
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Prolonged Seizures
The APA ECT Task Force defines a prolonged seizure as greater than 180 seconds. The British 
Royal College of Psychiatrists defines it as 120 seconds. Prolonged seizures may lack a motor 
component; this is one of the most compelling arguments in favour of EEG monitoring in ECT.
Possible remedies are to 
■ Abort the seizure with a benzodiazepine (diazepam, midazolam), or with an anticonvulsant 
anaesthetic agent (thiopental) intravenously.
■ Intubate if necessary.
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Evaluation of Individual Courses of Treatment
Before an index course of ECT treatment, each patient should have a treatment plan specifying 
criteria for remission. The patient’s symptoms should be documented before a course of treatment 
in order to be able to assess progress in specific target symptoms during treatment. A baseline 
clinical global impression or the use of a rating scale like the Hamilton Rating Scale for Depression
may be helpful.
Clinical assessment should be performed and documented by the attending physician before
the course of ECT, and weekly during the course of ECT. If performed, cognitive assessments should 
be done at least 24 hours after the ECT treatment.
The total number of ECT treatments required by a patient should be guided by the patient’s
degree and rate of clinical improvement, and the development and severity of cognitive adverse
effects. The frequency of ECT treatments should be guided by the severity of illness and the 
development and severity of adverse effects.
TECHNIQUE, EQUIPMENT, AND EVALUATIONC H A P T E R  4
Evaluation of Individual Courses of Treatment, continued
Frequency and Number of Treatments
It is usual practice to do 2 or 3 ECT treatments per week, administered on non-consecutive
days. In a major depression, a course of ECT usually consists of 6-12 treatments.
The use of daily treatments may be useful early in the treatment course when rapid response
is important, such as mania, catatonia, high suicide risk, and severe inanition. With bilateral treat-
ments, prolonged daily treatments increase the risk of cognitive impairment; the use of frequent
treatment regimens has not been justified.
The use of multiple ECT (the delivery of more than one adequate seizure per treatment session)
is not recommended.
For those patients who have improved with ECT treatments, the ECT treatment course should
be ended or tapered as soon as it is evident that a maximum response has been attained.
If confusion or marked deterioration in cognitive functioning occurs associated with ECT, consider
the following remedies
■ Review potential medical and medication causes.
■ Reduce treatment frequency (e.g., from 3 treatments per week to 1 – 2 treatments per week).
■ Reduce the stimulus dose.
■ Change electrode placement from bilateral to right unilateral.
■ Suspend treatments until cognitive functioning improves.
If there is a slow or minimal clinical improvement after 6 – 10 treatments, the indication for 
continued ECT should be reassessed. If the decision is to continue with ECT treatments, consideration
should be given to optimize ECT technique by
■ Increasing the stimulus intensity.
■ Changing from unilateral to bilateral electrode placement.
■ Reducing or removing medication that may decrease response (e.g., benzodiazepines, 
anticonvulsants, propofol).
If repeated courses of ECT are necessary, the cognitive effects associated with prior treatment
courses should be taken into consideration. If cognitive deficits are persistent and severe, a cumula-
tive effect can occur with subsequent ECT treatments, especially with bilateral electrode placement.
It is recommended that after 15 ECT treatments, a formal reassessment be done, including 
a second opinion.
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Lack of Response to ECT
Patients should not be considered ECT failures or non-responders until they have had at least 
10 treatments, and attempts have been made to optimize ECT response by
■ Increasing the stimulus intensity.
■ Changing electrode placement.
■ Reducing or stopping medications that may effect response by effecting the seizure threshold 
(e.g., benzodiazepines, anticonvulsants, propofol).
■ Changing medication strategies.
There are no clear strategies in treatment choices for ECT treatment non-responders. 
Some ECT practitioners try
■ Psychotropic medication trials, different agents than before, or combinations.
■ ECT and psychotropic medication.
■ A different type of ECT: high-dose bilateral ECT treatment.
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Evaluation of Individual Courses of Treatment, continued
TECHNIQUE, EQUIPMENT, AND EVALUATIONC H A P T E R  4
References
1. American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of 
Electroconvulsive Therapy. 2nd edition. Washington, DC, American Psychiatric Press, 2001
2. Lawson JS, Inglis J, Delva NJ, Rodenburg M, Waldron JJ, Letemendia FJ. Electrode placement in ECT: 
cognitive effects. Psychological Medicine 1990; 20:335–344
3. Swartz CM. Asymmetric bilateral right frontotemporal left frontal stimulus electrode placement 
for electro convulsive therapy. Neuropsychobiology 1994; 29:174–178
4. Petrides G, Fink M. The “half-age” stimulation strategy for ECT dosing. Convulsive Therapy 1996; 
12:138–146
5. Boylan LS, Haskett RF, Mulsant BH, Greenberg RM, Prudic J, Spicknall K, Lisanby SH, Sackeim HA. 
Determinants of seizure threshold in ECT: benzodiazepine use, anesthetic dosage, and other 
factors. Journal of Electroconvulsive Therapy 2000; 16:3–18
6. Beyer, J, Weiner, RD, Glenn, MD. Electroconvulsive Therapy: A Programmed Text, 2nd edition; 
APA, 1998
84 C H A P T E R 4E L E C T R O CO N V U L S I V E T H E R A P Y G U I D E L I N E S
Chapter 5
M A N AG E M E N T  O F  A DV E R S E  E F F E C TS
Postictal Delirium
Some patients develop postictal delirium following ECT.
This is associated with marked agitation, disorientation, poor
response to commands, and a sympathetic response. Bilateral
electrode placement, high-intensity stimulation, and pre-exist-
ing cerebral impairment may increase risk for postictal deliri-
um. It may take patients 5 - 45 minutes to recover. They are
often amnesic for the episode. There is a risk of injury to 
the patient or staff due to marked agitation or thrashing.
Depending on the severity of the symptoms, postictal delirium
can be managed supportively, with reassurance or pharmaco-
logically, with intravenous or intramuscular benzodiazepine
agents (e.g., midazolam), or intravenous haloperidol.
If postictal delirium is recurrent or severe, it can be man-
aged prophylactically with the use of the above agents after the
onset of spontaneous respiration.
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Cognitive Changes
The presence and severity of confusion and changes in cognitive functioning should be moni-
tored during a course of ECT by reviewing nursing notes, bedside assessment of orientation and
memory, and/or standardized testing such as the Folstein Mini-Mental Status Examination.
Assessment should be carried out before ECT and at least weekly throughout the index course.
Cognitive assessment should be performed whenever possible at least 24 hours following an ECT
treatment.
If there is a substantial deterioration of cognitive functioning during an ECT course, the physician
administering ECT should
■ Review the contributions of concomitant medications or the patient’s medical status.
■ Consider changing from bilateral electrode placement to right unilateral electrode placement 
during treatment.
■ Consider decreasing the stimulus dosage.
■ Change the interval between treatments; for example, if treatment frequency started at 3 times 
a week, decrease it to 1–2 times a week.
■ Consider suspending a course of treatments.
If cognitive changes persist after completion of the course of ECT, a plan should be made for 
post-ECT follow-up, assessment and management.
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Treatment Emergent Hypomania/Mania
A hypomanic or manic switch can occur during a course of ECT. In 1992, Angst and Angst1 pub-
lished a retrospective study of 1,057 hospital admissions between 1920 and 1981. They found that
12% of those diagnosed as endogenous depression and treated with ECT switched to hypomania. In 
the group diagnosed as psychotic depression, 10% switched to hypomania with ECT, and in the 
psychotic bipolar depressed patients, 32% switched to hypomania with ECT. The switch to mania 
or hypomania occurred more often in bipolar patients, or with patients with a family history 
of bipolar disorder. 
There are no present established treatment guidelines for treating hypomanic or manic 
symptoms that occur following ECT treatments. Strategies can range from
■ Stopping ECT and treating the manic symptoms with a mood stabilizer and/or antipsychotic.
■ Suspending further treatments and observing the patient.
■ Continuing ECT treatment to treat both the manic and depressive symptoms.
Delirium with euphoria, or “organic euphoria,”2 can occur following ECT. This is characterized by
confusion, disorientation and cognitive impairment. There is an associated silly, inappropriate 
quality to the patient’s mood. This is usually a transient state lasting a few hours to days. Recovery
can be facilitated by4
■ Increasing the time between treatments.
■ Decreasing the stimulus intensity.
■ Changing from bilateral to unilateral electrode placement.
Other Adverse Effects
If there is any sudden onset of new risk factors, or worsening of the risk factors identified 
pre-ECT, these risk factors should be evaluated before the next ECT treatment. The patient’s 
complaints concerning ECT should also be considered.
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Chapter 6
D O C U M E N TAT I O N  O F  I N D I V I D UA L  CO U R S E S
Documentation of the Course of ECT
The Head of the Department of Psychiatry is responsible 
to ensure that there are policies in place to support adequate 
documentation of ECT. Documentation is an important aspect 
of ECT in order to provide the basis for continued assessment
and reassessment of the patient’s progress, and to provide a
guide to effective treatment.
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Documentation of the Course of ECT, continued
Before an Index ECT Course
The attending psychiatrist should document the following items in the patient’s chart; the treating
psychiatrist should confirm that they are documented
■ Indications for ECT referral.
■ Assessment of benefits and risks.
■ Mental status, including target symptoms and base line cognitive functioning 
(e.g., Folstein Mini-Mental State Examination).
■ Signed consent document.
■ Charting recording the process of establishing informed consent.
■ Appropriate physical evaluation within 10 days before starting an inpatient course of treatment, 
and 30 days before the start of an outpatient course of ECT.
■ Pertinent laboratory investigations. Although there are no routine requirements for investigations,
and investigations are patient- and hospital-specific, it is recommended that an EKG be done for 
patients over 45 years old.
■ Consultation reports as indicated (anesthetic or medical).
Checklists are encouraged. The following examples appear at the end of this chapter
■ UBC Mood Disorders Centre ECT Checklist (see Appendix A).
■ Vancouver Hospital ECT Therapy Treatment Record (see Appendix B).
■ Riverview Hospital Pre-ECT Medical Checklist (see Appendix C).
■ St. Joseph’s General Hospital ECT Checklist (see Appendix D).
Before a Maintenance Series of ECT
Before beginning a maintenance series of ECT, the treating psychiatrist should confirm that 
the patient’s clinical record includes documentation of the following material
■ Indications for maintenance ECT
■ A signed consent form at least every 6 months or 15 treatments
■ Charting of the elements of the informed consent process.
90 C H A P T E R 6E L E C T R O CO N V U L S I V E T H E R A P Y G U I D E L I N E S
DOCUMENTATION OF INDIVIDUAL COURSESC H A P T E R  6
Documentation of the Course of ECT, continued
Between ECT Treatment Sessions (Index or Maintenance)
The attending physician should chart in the patient’s clinical record at least weekly during an
index ECT course. The charting should contain information about therapeutic response and adverse
effects. Cognitive effects can be determined by reviewing the nursing notes, and through bedside
assessment of orientation and/or memory, and/or autobiographical memory. The use of standardized
testing such as the Folstein Mini-Mental State Examination can be helpful. Cognitive assessment
should be done and recorded at baseline before ECT, and one week following the last ECT treatment
in an index course. For maintenance, cognitive assessment should be done as a baseline prior to
starting, and monthly thereafter.
There should also be communication between the attending and treating physicians. The
forms at the end of this chapter are examples of what can be used
■ Maintenance ECT Record (see Appendix E).
■ Riverview Hospital ECT Progress Records (see Appendix F).
Using such forms, the attending physician can fax information back to the treating physician
about the progress of the patient between ECT treatments and any development of adverse effects. 
If 15 ECT treatments are exceeded in an index course of treatment, a second opinion should 
be documented on the chart justifying the provision of further treatment. With maintenance ECT, 
documentation of therapeutic response and cognitive effects should occur either before each 
treatment, or at least monthly, if the patient is stable and treatments occur more than twice 
per month.
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Documentation of the Course of ECT, continued
At the Time of Each ECT Session
For each treatment session, at least the following information should be documented in the patient’s 
clinical record
Pre-Treatment
■ Baseline vital signs
■ Medication, including dosage given before entering the treatment room.
■ Any changes in risk factors, presence of adverse effects, or complications, should be noted in the 
chart before treatment.
Treatment
■ Vital signs taken during treatment.
■ Notes from the anesthetist describing the patient’s condition while in the treatment.
■ Medication given in the treatment, including dosage.
■ Stimulus electrode placement (bilateral, right unilateral, left unilateral).
■ Stimulus parameter settings for each stimulus.
■ Seizure duration, noting whether motor or electroencephalographic, the quality of the EEG 
seizure, and the quality of suppression of the EEG seizure.
■ Any adverse effects or complications that occur during treatment, and the steps taken to deal 
with them, charted by the treating psychiatrist.
Post-Treatment
■ Vital signs post-treatment.
■ Medication given post treatment, including dosage.
■ Notes from the anesthetist describing the patient’s condition in recovery.
■ Notes from the recovery nurse, anesthetist, or treating psychiatrist documenting occurrence and 
management of any complications during recovery.
■ The patient’s condition on leaving the recovery area.
It is useful to keep a copy of treatment information for outpatients in the outpatient clinic
treatment area, especially a copy of the consent, and data on electrode placement, stimulus parame-
ters, seizure duration, anesthetic record, and adverse effects.
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Following Completion of the Index ECT Course 
or Maintenance ECT Series
The attending physician should enter the following information in the clinical record
■ A summary of overall therapeutic outcome and adverse effects experienced as a result 
of the ECT course or series, and the rationale for choice of endpoint
■ A plan for post-ECT clinical management and any plans for follow-up of adverse effects.
The attending physician may find the form “Riverview Hospital ECT Outcome Evaluation” use-
ful as an example, which appears at the end of this chapter. (See Appendix G.)
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Documentation of the Course of ECT, continued
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List of Chapter 6 Appendices
Appendix A:
ECT Check List, which is revised from the UBC Mood Disorders original
Appendix B:
Electroconvulsive Therapy Treatment Record, Vancouver Hospital & Health Sciences Centre,
Department of Psychiatry. (Two-sided form listed as Page 1 and Page 2 in this document.) 
Appendix C:
Riverview Hospital Pre-ECT Medical Checklist. 
Appendix D:
St. Joseph’s General Hospital, Comox, British Columbia. Electroconvulsive Therapy Checklist. 
Appendix E:
Maintenance ECT Record. This document was created for the Electroconvulsive Therapy Guidelines
by Dr. M.L. Donnelly. (Two-sided form listed as Page 1 and Page 2 in this document.) 
Appendix F:
Outpatient ECT Progress Record Riverview Hospital.
Appendix G:
ECT Outcome Evaluation Riverview Hospital.
All of these documents may be used where appropriate to be helpful, as long as the origins are cited.
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ECT Checklist
NAME:___________________________________  SEX:______
DOB:_________________PHN:__________________________
HOSPITAL___________________________________________
UBC MOOD DISORDERS ECT CHECKLIST (Revised)
PRIMARY DIAGNOSIS: INDICATIONS FOR ECT: (check all that apply)
■  Major Depressive Disorder ■  Rapid response needed
■  Bipolar Disorder, Depressed ■  Acute suicidality
■  Bipolar Disorder, Manic ■  Physical deterioration
■  Schizophrenia ■  Refractory to medications
■  Schizoaffective Disorder ■  Other (please specify):
■  Parkinson’s Disease
■  Other (please specify):
PREVIOUS ECT RESPONSE:     ■  Not applicable   ■  Good response   ■  Limited or no response
PATIENT: ■  Voluntary ➡➡ ■  Risks/benefits explained    ➡ ■  Patient consent signed
STATUS:      ■  Involuntary   ➡➡ ■  Second opinion completed  ➡ ■  Medical director consent
signed (± patient consent)
PRE-ECT WORKUP:      ■  Physical Examination ■  Lab ■  ECG (if necessary)
■  Anaesthesia consult ■  ECT orders written
OUTCOME MEASURES  PRE-ECT    POST-ECT (at time of new consent for 
maintenance, either 6 months or 15 treatments)
Folstein Mini-Mental State Exam
Clinical Global Impression ■ Not at all ill
■ Borderline ill
■ Mildly ill
■ Moderately ill
■ Markedly ill
■ Severely ill
■ Extremely ill
Hamilton Depression Rating 
Scale (optional)
17-item
7-item
24-item total
Beck Depression Inventory 
(optional)
Geriatric Depression Scale
or Other Depression Scale
REASON ECT STOPPED:      ■ Maximum Benefit ■ Adverse Effects ■ Limited or no response
From UBC Mood Disorders Centre. Used with permission.
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■ Very much improved
■ Much improved
■ Minimally improved
■ Not improved
■ Worse
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Chapter 7
CO N T I N UAT I O N  A N D  M A I N T E N A N C E  E C T
General Considerations
Traditionally when treating major depression, once remis-
sion of symptoms has been achieved, the 6-month period there-
after is described as the “continuation phase” of treatment,
while treatment beyond the 6 months is classified as the “main-
tenance phase.”1 The continuation phase represents the period
of particular vulnerability for re-emergence of symptoms, and
pharmacotherapy is often recommended. In practice, it is diffi-
cult to distinguish between relapse (symptoms re-emerging dur-
ing the continuation phase) and recurrence (symptoms re-
emerging in the maintenance phase), thus this delineation may
be less clinically useful.2 This period of vulnerability may be
longer in the elderly, ranging from 12 months3 to 2 years.2,4
Longer treatment for at least 2 years can also be appropriate for
other vulnerable groups with major depression associated with
chronic episodes, severe or life-threatening episodes, psychotic
episodes, difficult to treat episodes, 3 episodes or greater, and fre-
quent episodes (2 episodes or greater in 5 years).2
continued . . .
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General Considerations
A number of studies have found high rates of relapse or recurrence in the 6- to 12-month period 
post-ECT, particularly without adequate continuation pharmacotherapy for depression.5 Appropriate
continuation pharmacotherapy can significantly reduce these rates. Continuation ECT (C-ECT),
extending for the 6 to 12 months after acute ECT treatment, and maintenance ECT (M-ECT), 
extending beyond the C-ECT period, appear to be effective in preventing relapse and recurrence 
in all conditions with primary indications for use,6 such as depression, mania, and schizophrenia.
(See “Primary Indications for Use” in Chapter 3.) It can also be effective for Parkinson’s disease.7,8
However, few prospective studies have compared C-ECT or M-ECT alone with pharmacotherapy.
One recent study concluded ECT alone did not confer any advantage over continuation pharma-
cotherapy at 6 months in pre-ECT labelled “medication resistant” patients (50% relapse rate), but the
comparison group was literature-based.9 On the contrary, M-ECT combined with medication over one
year for those with major depression or schizoaffective disorder conferred better outcome prospec-
tively than pharmacotherapy alone.10 Finally, a recent retrospective case controlled series yielded a
similar beneficial result of C-ECT combined with medications.11 This finding also appears to apply to
an older group of patients (mean age 70) from an older, naturalistic study.12 In conclusion, retrospec-
tive data and clinical experience strongly indicate there can be a clear benefit from C-ECT or M-ECT
in certain cases; more prospective data are needed to confirm this observation.
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Recommendations for Use
According to the APA Guidelines,13 after a successful index course of ECT, continuation of ECT should 
be considered when
■ Pharmacotherapy has been ineffective or unsafe in preventing relapse or recurrence.
■ The patient (or substitute decision-maker) prefers to continue with ECT, and is willing to comply 
with the overall treatment plan, including behavioural restrictions associated with outpatient ECT.
Sparse data currently available indicate C-ECT or M-ECT combined with pharmacotherapy pro-
vides better outcomes than ECT or pharmacotherapy alone in selected patients. Further research,
including the results of the ongoing 5-year NIMH-funded Consortium for Research in ECT (CORE), con-
tinuation ECT vs. pharmacotherapy prospective trial, will help clinicians decide whether single or
combination treatment would be the most effective.
Some of those who remain well with C-ECT will benefit further from M-ECT. The duration of M-
ECT to prevent recurrence is unclear, but there may not need to be a limited duration specified, or
maximum number of M-ECT treatments, in those who particularly have “a strong history of recurrent
illness, or when present or past attempts to stop or taper continuation treatment have been associated
with return of symptoms.”13
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Process and Evaluation
C-ECT and M-ECT are typically given as outpatient treatments, ranging from weekly to month-
ly. Some will be maintained at less frequent intervals, such as every 6 to 8 weeks. Consent, tech-
nique, and evaluation, as covered in other chapters here, are issues to be tailored to the outpatient.
It is suggested that
■ The responsibility between the attending physician and ECT practitioner regarding who should 
monitor for target symptoms and cognitive function, and how consent should be obtained and 
renewed, should be clear for each case.  In most instances, these would be the attending 
physician’s responsibilities.
■ The overall treatment plan should be reviewed and consent should be obtained at least every 
six months.13
■ A register of patients undergoing ECT is helpful. A readily-accessible site where consents can be 
stored and brought up with each treatment is optimal.
■ A discussion of the frequency of treatments and anticipated tapering schedule is strongly 
suggested before starting C-ECT.  One tapering schedule suggests weekly ECTs for 1 month, 
biweekly ECTs for 2 months, and monthly ECTs for 3 months. Because of the vulnerability for 
relapse in the continuation phase of treatment, one might not need to taper ECT at such a 
prescribed frequency. Instead, the schedule of ECTs could be guided by each individual’s clinical 
condition and his or her history of relapse when attempts have been made in the past to taper 
continuation treatment.
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Special Considerations: Dementia and ECT
There may be some patients undergoing ECT (i.e., demented, brain injured, or minors) who
may be incompetent to consent for C-ECT or M-ECT, but not commitable under the Mental Health
Act. In these cases consent from a substitute decision-maker must be obtained, as set out in the
Health Care (Consent) and Care Facility (Admission) Act or the Mental Health Act.
Of particular interest are those with co-existing dementia and depression, since there is consid-
erable overlap in symptoms associated with the diagnosis of each. Disturbances in mood and affect
seem to be more specific for mood disorder rather than motivational or vegetative symptoms.14
Scales such as the Geriatric Depression Scale can aid in diagnosis in the presence of mild to moderate
dementia,15 particularly if there are reliable informants around. Complicating the issue further is
that an index course of ECT may have a positive effect on general agitation in those with demen-
tia,16 as well as benefiting those demented with major depression,17 paralleling the efficacy of SSRIs
for treating anxiety or some behavioural disorders associated with dementia.18
These factors should be taken into account before embarking on C-ECT or M-ECT in those
patients with dementia. Clearly there will be those who attain a clear benefit in mood and affective
symptoms, with improvement in function or social interaction. However, there will be those who
become more placid due to less-specific effects of ECT, or due to a progression of dementia itself.
Thus, finding alternative pharmacologic or non-pharmacologic maintenance treatments other than
ECT would minimize risk of treatment in the long term. While C-ECT or M-ECT is considered a safe
treatment in dementia, and there is no evidence for alterations of brain structure from contempo-
rary ECT,19 there are no data available to indicate whether M-ECT can or cannot adversely influence
the cognitive deterioration in dementia. Therefore, for those with dementia, it is suggested that
■ There must be significant benefit observed with an acute course of ECT before recommending 
C-ECT or M-ECT.  There must be clear documentation of the indication for C-ECT or M-ECT, and the 
symptoms targeted.
■ The risks and benefits of C-ECT or M-ECT are specifically discussed with the patient or the patient’s
substitute decision-maker, and documented.
■ For those deemed to be incompetent to consent, a second psychiatric opinion is advisable, 
preferably from a geriatric psychiatrist, addressing both the clinical issues and the competency 
to consent issue.
■ A review of the treatment plan and the need to continue ECT should be done every 6 months, 
including a re-evaluation of cognitive function and a discussion of this with the patient or the 
patient’s substitute decision-maker.
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References, continued
Chapter 8
N U R S I N G  CO N S I D E R AT I O N S
Recommendations on Nursing Responsibilities
ECT is provided in a variety of settings in British Columbia 
hospitals. The following section outlines recommendations
regarding nursing responsibilities in instances where the 
hospital in question has a designated suite for the delivery of
ECT, and when the hospital delivers ECT in the OR, PAR, or ER.
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Staffing for a designated ECT Suite
Treatment Coordinator
Qualifications
■ RN/RPN with training in the use of ECT.
Responsibilities
■ Book and schedule treatments.
■ Contact outpatients to advise them of their treatment time.
■ Provide education and support to outpatients and families as required.
■ Assemble charts for outpatients.
■ Ensure ECT equipment is available at the treatment area.
■ Ensure treatment medications and emergency medications are available and current.
■ Set up the treatment room.
■ Assign designated nursing staff to specific roles during the treatment.
■ Provide emergency interventions as required.
■ Facilitate and organize orientation of new staff to ECT.
■ Facilitate and organize in-service educational programs related to ECT.
■ Develop guidelines for the nursing care of patients having ECT.
■ Participate in the development of patient education materials.
Treatment/Recovery Room Nursing Staff
Qualifications
■ RN with critical care training or at least recent medical-surgical experience.
Responsibilities
■ Assist the treatment room coordinator in the treatment area as directed.
■ Monitor patients in the post-anesthetic recovery room.
■ Provide emergency interventions as necessary.
■ Determine when to notify the anesthetist and/or the treating physician.
■ Arrange for the patient’s transfer back to the inpatient ward or for discharge when he 
or she is stable. (See the section “Pre- and Post-ECT Outpatient Nursing Care.”)
■ Provide reassurance and support to patients.
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Staffing for ECTs Performed in the OR, PAR, or ER
Recommendations
■ Ideally, designate a member of the nursing staff from the psychiatric unit as coordinator of the 
ECT program, and designate at least 2 members of the nursing staff in the treatment area to be 
responsible for the ECT treatments.
■ Provide training for above staff members (according to training guidelines).
■ Ensure designated staff is assigned to the treatment area.
Responsibilities
Psychiatric Unit Staff
■ Provide education and support to patients and families.
■ Ideally, accompany patients to the treatment area and remain with them until treatment begins.
■ Attend the recovery area to assist with agitated patients as required.
See the section “Pre and Post-ECT Inpatient Nursing Care” for further details. 
Staff in Pre-/Post-ECT Waiting Areas (Day Care Surgery)
See the section “Pre and Post-ECT Outpatient Nursing Care.”
Coordinator of ECT Program
■ Book and schedule treatments.
■ Contact outpatients to inform them of their treatment time.
■ Provide education and support to outpatients and families as required.
■ Assemble charts for outpatients.
■ Ensure ECT equipment is available at the treatment area.
■ Facilitate and organize orientation of new staff to ECT.
■ Facilitate and organize inservice educational programs related to ECT.
■ Develop guidelines for the nursing care of patients having ECT.
■ Participate in the development of patient education materials.
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Staffing for ECTs Performed in the OR, PAR, or ER, continued
Treatment/Recovery Room Nursing Staff
■ Set up the treatment area.
■ Ensure treatment medications and emergency medications are available and current.
■ Assist anesthetist/treating physician as necessary.
■ Monitor patients in Post Anesthetic Recovery area.
■ Provide emergency interventions as necessary.
■ Determine when to notify the anesthetist and/or treating physician.
■ Arrange for the patient’s transfer back to inpatient ward or for discharge when he or she is stable.
Goals of Nursing Care
The patient will
■ Understand the need for having ECT, the possible side effects and the procedures to be carried out.
■ Experience minimal physical side effects and psychological discomfort from ECT.
■ Have his/her safety maintained before, during, and after ECT.
Interventions
Treatment Coordinator
When Referral for ECT Is Received
■ Ensure the patient’s clinical record is up-to-date and includes the following
• Referral and booking forms.
• Progress notes from the referring psychiatrist.
• Current medication list.
• ECT treatment records.
• Nursing progress notes.
• Current consent form.
■ Assess and arrange for education required, including family members as necessary.
Pre- and Post-ECT Outpatient Nursing Care
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Pre- and Post-ECT Outpatient Nursing Care, continued
Interventions, continued
Staff in the Pre-/Post-Treatment Waiting Room
Pre-ECT
■ Receive the patient in the designated area and ensure all necessary forms are with the chart.
■ Collect baseline clinical data, including VS and mental status.
■ Complete the ECT/Pre-Op checklist.
■ Ensure prescribed pre-ECT medications have been taken.
■ Ensure the patient has been NPO 
• for treatments given in the morning: from midnight
• for treatments given later in day: according to hospital policy (no food for 5-6 hours, and only 
clear fluids up to 2 hours before the treatment).
■ Assist the patient to change into hospital attire, according to hospital policy.
■ Assess the patient’s level of anxiety.
■ Give the patient reassurance and support.
■ When possible, ensure a staff member or responsible adult is available to remain with the patient 
before entering the treatment area.
■ Ensure the patient voids before entering the treatment area.
■ Assess the patient’s potential for incontinence. Suggest wearing disposable briefs only if 
necessary, and with all geriatric patients.
Post-ECT
■ Provide the patient with light breakfast/fluids.
■ Give the patient reassurance and support.
■ Assess the patient’s vital signs and level of orientation before discharge.
■ Ensure that the patient is accompanied by a responsible adult when leaving the treatment 
facility post-ECT, and will be escorted home.
■ Instruct the patient and the accompanying adult regarding the need to
• Be aware of possible side effects from the treatment or the anesthetic.
• Report any untoward reactions to the attending physician.
■ Instruct the patient not to drive a vehicle for 24 hours.
■ Ensure the patient’s personal effects go with him or her.
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Pre- and Post-ECT Outpatient Nursing Care, continued
Staff in Treatment and Recovery Areas
See the section “Nursing Responsibilities in Treatment Areas.”
Documentation
Complete ECT Nursing Record and Nursing Progress Notes, including any untoward events.
Interventions
Pre-ECT
When ECT is ordered
■ Assess the education required, including family members as necessary.
■ Implement the education plan.
■ Document the education carried out and its outcome.
■ Ensure facility-appropriate chart forms are on patient’s chart, including
• The consent form..
• Checklists.
• Record of anesthesia.
• Record of ECT.
The Day before ECT
■ Assess the patient’s physical and mental status.
■ Commence the ECT/Pre-Op checklist.
■ Encourage and/or assist the patient with personal hygiene, especially hair-washing.
■ Encourage the patient to express concerns and feelings about his/her condition and ECT.
■ Maintain NPO from midnight. Remove all food and fluids from the bedside.
Pre- and Post-ECT Inpatient Nursing Care
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Pre- and Post-ECT Inpatient Nursing Care, continued
Interventions, continued
The Morning of ECT
Complete the ECT/Pre-Op checklist.
■ Confirm NPO has been maintained with the patient (according to outpatient guidelines).
■ Assess the patient’s potential for incontinence. Encourage the patient to void immediately before 
leaving ward. Suggest wearing disposable briefs only if necessary, and with all geriatric 
patients.
■ Assess the patient’s level of anxiety.
■ Give the patient reassurance and support.
■ When possible, accompany the patient to the treatment area.
■ When possible, remain with the patient to provide support until he or she enters the 
treatment room
Post-ECT
On the patient’s return to the ward
■ Assess the patient’s physical and mental status.
■ Take the patient’s blood pressure, pulse, and respirations within 5 min. of his or her return 
to the ward.
■ Assess the frequency of observation required based on the patient’s return to Pre-ECT vital signs 
and level of consciousness (e.g., q 15 min., q 30 min., q 1 hr).
■ Assess the safety of the patient’s environment and his or her readiness to ambulate and to swal
low before giving morning medication and breakfast.
■ Assess and document any side effects of the treatment.
■ Ensure the patient is accompanied when leaving the ward any time up to 24 hours 
post-ECT. 
■ Instruct the patient not to drive a motor vehicle for 24 hours post-ECT.
■ Alert the patient’s family and friends of the need for supervision for a minimum 
of 24 hours post-treatment.
Documentation
Complete the following documentation
■ Pre-treatment assessment data and interventions.
■ Patient/family education, including their response to the education.
■ Post-treatment assessment data and interventions.
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Nursing Responsibilities in Treatment Areas
Nursing Care Goal
The patient will have safety maintained immediately before, during and following ECT.
Directives
A patient will be assessed for transfer/discharge from the recovery room post-ECT when
■ The pre-and post-ECT scores correspond using a Post-Anesthetic Discharge Scoring System 
(see Appendix A). This form is part of the patient chart.
■ The patient's vital signs are ±20% of baseline.  
Inpatients
A recovery room nurse may transfer a patient to the unit of origin when the patient achieves the
above patient specific discharge criteria. A physician will assess patients not meeting the discharge
criteria in order for them to be transferred.
Outpatients
It is recommended that facilities providing outpatient ECT develop a policy statement and proce-
dures that will address the discharge process of patients from the Post-Anesthetic Recovery room.
Such a policy with corresponding procedures ought to include
■ Criteria to be met before discharge (see above) using the  discharge protocol form.
■ Who may discharge the patient (e.g., a nurse certified to discharge the patient).
■ Whom to call if a patient does not meet the discharge criteria.
A doctor’s order for discharge is required if the above policy is not in place.
Interventions
The following interventions are suggested as guidelines and may vary according to hospital-specific
policies, procedures, or practices.
In the Treatment Room
■ Ensure all equipment is available (see Chapter 4, “Technique, Equipment, and Evaluation).
■ Ensure that all required chart documentation is accurate and complete.
■ Review the ECT checklist.
■ Confirm that pre-ECT medications have been taken.
■ Assist the patient onto the stretcher.
■ Establish intravenous access according to the treating physician’s order and facility practice.
■ Pre-ECT, assess and record the patient’s
• Level of consciousness.
• Respiratory status.
• Muscle strength.
• Skin color.
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■ Check and record BP and P pre-ECT.
■ Cleanse electrode placement sites with alcohol swabs.
Interventions, continued
In the Treatment Room, continued
■ Attach ECG and EEG electrodes.
■ Attach the oximeter sensor.
■ Record O2 saturation on room air.
■ Assist the anesthetist as required.
■ Apply the BP cuff to limb as directed, and inflate 220 mm/hg before the injection of succinylcholine.
■ Assist with the placement of ECT electrodes.
■ Assist the treating physician with the treatment by holding the electrodes in place, and triggering 
the electrical stimulus.
■ Apply gentle pressure on the patient’s legs and arms to protect limbs from injury.
■ Deflate BP cuff when the EEG has indicated seizure activity has stopped.
■ Post seizure, record BP, pulse, and O2 saturation.
■ Remove the oximeter sensor, ECG leads, and EEG leads when directed.
■ Assist in turning the patient to the post-anesthetic position.
■ Assist with transferring the patient to the recovery room.
In the Recovery Room
■ Prepare the recovery room for receiving patients post treatment
• Check the wall suction and oxygen.
• Check the pulse oximeter.
• Test the patient monitoring system (if in PAR/ER).
■ Receive a verbal report from the treatment room nurse and anesthetist.
■ Commence 02 at 6–10 liters/min.
■ Attach the oximeter.
■ Check and record the patient’s level of consciousness, respiratory status, muscle strength, 
and skin color
• On admission.
• Q5 minutes until it is equal to the pre-ECT score.
• On discharge if more than 15 minutes have elapsed since the last recording.
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Interventions, continued
In the Recovery Room, continued
■ Check and record BP, P, and R
• On admission.
• Q5 minutes until vital signs are ±20% of baseline.
• On discharge if more than 15 minutes have elapsed since the last recording.
■ Check and record O2 saturation
• On admission.
• Q5 minutes until O2 > 95.
• Before discharge if more than 15 minutes have elapsed since the last recording.
■ Assist the patient to expel the artificial airway prn.
■ Administer suction if required.
■ Discontinue 02 as indicated by the patient’s condition, and check O2 saturation on room air.
■ Elevate the head of the stretcher.
■ Check the patient’s
• Mouth and teeth for injury.
• ECT electrode sites for redness and/or blistering.
Notify the physician and treatment room nurse if you note an injury, and complete 
an incident report as appropriate.
■ Re-orient the patient to person, time, and place.
■ Reassure the patient that treatment is over.
■ Discontinue intravenous access.
■ Notify the ward and accompanying adults that the patient is ready to be discharged from 
the recovery room.
■ Ensure the patient’s personal effects go with him or her.
■ Give a verbal report to the ward nurse or, in the case of an outpatient, to the accompanying adult.
Documentation
Complete the ECT/PAR Nursing Record, including any untoward events. 
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POST-ANESTHETIC DISCHARGE SCORING SYSTEM
SCORE CRITERIA ADM POST ECT 5 MIN 5 MIN      DIS
Resp.
2 Breathes deeply or coughs
1 Dyspnea or limited breathing
0 Apnea/Airway requires attention
O2 Sat
2 >95%
1 90-95 %
0 < 90%
LOC
2 Fully awake
1 Arousable on calling
0 No response
Circ
2 BP ± 20% preanaesthetic level
1 BP ± 20-50%  preanaesthetic level
0 BP ± 50% preanaesthetic level
Color
2 Normal/Pink
1 Pale, dusky, blotchy, jaundiced
0 Cyanotic
Strength
2 Hand grasps strong
1 Hand grasps weak
0 No movement
TOTAL SCORE
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Chapter 9
A N E S T H E S I A  G U I D E L I N E S
Requirements
All anesthesia providers must adhere to the Guidelines 
to the Practice of Anesthesia recommended by the Canadian
Anesthesiologist’s Society (revised edition 2000).1 These 
guidelines address minimum requirements pertaining to
■ the role of an anesthesiologist in patient care
■ facility and equipment requirements in the anesthetizing 
location and recovery area.
Anesthetizing locations outside an accredited hospital 
operating room suite must follow the “British Columbia 
College of Physicians and Surgeons policy for non-hospital 
medical/surgical facilities.”2
When anesthesia practitioners do not have the necessary 
equipment or staff ’s lack the necessary training or skills to 
safely and efficiently administer general anesthesia for electro-
convulsive therapy and attend to the potential complications, 
or when the patient’s medical condition dictates, a prudent
practitioner should refer the patient to another practitioner 
or facility to provide optimal care.
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Pre-Anesthetic Period
Anesthesia Consultation/Evaluation
An anesthesia consultation/evaluation should be requested before the first ECT, or during 
maintenance ECT when there is a significant change in the patient’s medical status or medications.
All patients with an ASA rating of 3 or above should have a consultation. The objectives of a 
consultation are to
■ Determine the indication for ECT and any specific requirements that pertain to the 
proposed ECT therapy.
■ Determine the history of anesthetic course during any prior ECT.
■ Identify risk factors that may increase perioperative risk, and to take or suggest measures that 
would try to minimize that risk, including obtaining opinions from other consultants, laboratory, 
or investigative testing that may be deemed appropriate from the history and physical 
examination of the patient. Where risks are considered to be high, cancellation of the proposed 
procedure may be in the patient’s best interests.
During the evaluation,
■ A written report should be provided, documenting history and physical status, ASA classification, 
and specific concerns that may impact the proposed treatments and/or affect patient outcome.
■ Pre-operative modification of antidepressant drugs should be discussed with the attending 
psychiatrist.
■ Pre-operative orders to be administered before each treatment should be provided.
Pre-Operative Laboratory Testing
■ No routine laboratory investigations are necessary; ordering of laboratory tests should be guided 
by the presence and severity of medical risk factors.
■ It is suggested that practitioners follow the BC guidelines to electrocardiograms and pre-operative 
testing.3
■ The potential for drug interaction and the autonomic instability that may manifest itself during 
ECT treatments should guide the clinician to consider obtaining baseline investigations that may 
not necessarily follow the BC guidelines to ECG and laboratory testing. 
■ Hospital or treatment facilities may define their own guidelines, depending on their 
specific circumstances.
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Pre-Anesthetic Period, continued
Oral Intake
Minimum duration of fasting should be
■ 8 hours after a meal that includes meat, fried, or fatty foods.
■ 6 hours after a light meal (such as toast and a clear fluid).
■ 2 hours after clear fluids.
If necessary, patients should be maintained on a level of observation sufficient to ensure 
compliance. 
Should risk factors for aspiration be present, the anesthesiologist may elect to prolong the
patient’s NPO status, and pre-operatively prescribe a prokinetic agent such as metoclopramide, an
H2 receptor blocker such as ranitidine, or a non-particulate antacid such as sodium citrate. This
would be ordered in the pre-operative orders.
Patients at risk for relative dehydration should have an intravenous commenced early in the 
pre-operative period.
All diabetics should have a baseline glucometer reading performed. Thereafter, if indicated, a 
dextrose containing intravenous should be commenced.
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Pre-Anesthetic Period, continued
Medications
Most regular medications should be continued during a course of ECT. They may be given with a sip
of water the morning of treatment. (See “Psychotropic Medications during ECT” in Chapter 4.)
Physiological Changes During ECT
■ Application of the electrical stimulus results in vagal stimulation regardless of whether a seizure 
is induced. The most apparent effect of this parasympathetic discharge is bradycardia. Asystole 
may occur, particularly in younger patients or individuals that have pre-existing cardiac 
conduction defects, or medications that affect conduction, such as beta-blockers.
■ Seizure induction results in a sympathetic discharge with release of catecholamines and a 
resultant tachycardia and hypertension. The rate/pressure product increases dramatically; this 
may place the myocardium at risk for ischemia.
■ Post seizure, baroreceptor-induced bradycardia may occur.
■ During the seizure, cerebral blood flow increases markedly, oxygen extraction increases, and 
glucose metabolism increases.
■ Cerebral autoregulation may be impeded, resulting in increased intracerebral pressure.
■ Cardiac arrhythmias are frequent, but are usually self-limiting.
■ Post-operative electrocardiographic changes showing ST-segment deviation and T wave inversion 
suggestive of subendocardial ischemia have been reported.
■ Systolic performance of the left ventricle has been shown to be transiently impaired in patients 
not felt to be at risk for cardiac ischemia.
■ Intraoccular and intragastric pressure increases.
The aforementioned physiological changes that may occur during ECT, coupled with the
administration of anesthetic agents, is what places patients “at risk” for ECT. It is these factors that
necessitate a complete evaluation of risk at the time of the anesthetic consultation. These risks must
be balanced against those associated with medication use.
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The Anesthetic Period
Unique Considerations
■ Current ECT practice requires a general anesthetic. 
■ Neuromuscular blockade is necessary to attenuate the musculoskeletal manifestations of the 
seizure and to enable airway control and patency to permit ventilation and oxygenation.
■ The selection of drugs and doses should be individualized to account for each patient’s 
unique requirements.
■ Potential drug interactions with antidepressants (e.g., MAOIs, lithium) must always be considered.
■ Seizures persisting for more than 180 seconds should be considered prolonged, and should be 
terminated pharmacologically.
The protection of the teeth and oral structures requires special attention
■ The electrical stimulus results in direct stimulation of the masseter, pterygoid, and temporalis 
muscles, causing an abrupt clenching of the jaw, despite muscle relaxation.
■ A flexible bite-block should be used to distribute the force of the jaw contracting, to enable 
protection of the teeth and other oral structures.
■ All patients, including edentulous patients, require a bite-block to be inserted.
■ Partial dentures may remain in as a support to protect single or vulnerable teeth.
■ The patient’s chin should be supported to keep the jaw tight against the bite-block during 
the stimulus.
■ A plastic airway (e.g., Guedel-type) should not be used as a bite-block.
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The Anesthetic Period, continued
Procedure
■ Perform equipment check, and ensure emergency drugs and apparatus are present, available, 
and functional.
■ Ensure that stretcher is capable of Trendelenberg positioning.
■ Review the patient’s chart, including prior ECT anesthetic records.
■ Ensure that the patient has an understanding of the proposed anesthetic.
■ Discuss the planned procedure with the attending psychiatrist, including
• Unilateral or bilateral electrode placement.
• The necessity to titrate stimulus intensity.
• The necessity to utilize proconvulsant drugs.
• The requirement for limb isolation to observe motor manifestations of seizure.
• The need for relative hyperventilation.
■ Establish intravenous access via an indwelling canula.
■ Ensure monitors are attached, and obtain a baseline recording of parameters.
■ Administer anesthetic drugs, ensuring adequate pre-oxygenation, airway control, and placement 
of the bite-block.
■ Administer intermittent positive pressure ventilation with 100% oxygen until the electrical 
stimulus, and continue post-stimulus until spontaneous and regular breathing are resumed.
■ Ensure electrical isolation and support the mandible in occlusion before the stimulus.
■ Ensure the patient’s positioning is optimal to ensure his or her safety.
■ When the patient is adequately anesthetized and haemodynamically stable, and muscle 
relaxation is optimized (90 seconds for succinylcholine), the ECT stimulus may be applied.
■ During and immediately post stimulus, special attention must be directed to
• Oxygenation and ventilation.
• Hemodynamic stability. The blood pressure cuff should be cycled every 1–2 minutes. (A manual 
cuff may be required to record pressure, since the automatic cuff ’s cycle time and accuracy may 
be impeded by wide fluctuations in the blood pressure or by the presence of tachy or brady 
dysrrhymias).
■ When the seizure has terminated, both in terms of motor and EEG evidence and hemodynamic 
stability is achieved, the patient may be placed in the lateral position to maintain airway patency.
■ Once the patient is stable, rousable, and maintains spontaneous ventilation, he or she may be 
transferred to the recovery area. Oxygen should be administered by facemask during transit.
■ The course of the anesthetic should be recorded.
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The Anesthetic Period, continued
Anesthesia Drugs
The ideal induction agent would provide a short induction time that assured complete amne-
sia/unconsciousness throughout the period of muscle relaxation, including the seizure, while provid-
ing rapid titratability, hemodynamic stability, and a rapid recovery profile. It should have minimal
to no effect on the seizure threshold, duration, or propagation of the seizure.
Methohexital
Methohexital was the most frequently-used induction agent for ECT, but is no longer available.
Sodium Thiopentone (Pentothal)
■ Sodium thiopentone is the current drug of choice in some treatment facilities.
■ This barbiturate increases the seizure threshold in a dose-dependent fashion.
■ Repeat dosing may cause a prolonged recovery period.
■ It is difficult to titrate to assure unconsciousness.
Propofol (Diprivan)
■ A dose of 0.75 – 1.5 mg/kg results in a significant reduction of the magnitude of hemodynamic 
changes that accompany ECT.
■ Propofol induces cerebral vasoconstriction, reduces cerebral blood flow and intracranial pressure, 
and decreases cerebral metabolic rate.
■ Anticonvulsant action reduces seizure duration significantly.
■ It is not shown to change therapeutic outcome compared to pentothal or methohexital.
■ There is pain on injection, which can be reduced by injecting into a fast-running intravenous 
placed into a larger bore vessel. (Lidocaine should not be added to propofol, since it will increase 
the seizure threshold.)
■ Propofol shows no benefit in the recovery profile compared to barbiturates (ECT use).
Muscle relaxants
■ Muscle relaxants are used to minimize risk of a skeletal injury during seizure.
■ Complete paralysis is neither desirable nor necessary, but should be tailored to the patient’s need.
■ A peripheral nerve stimulator allows a more accurate estimation of paralysis than clinical 
estimation.
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The Anesthetic Period, continued
Succinylcholine
■ Succinylcholine is the relaxant of choice in a dose of 0.5 – 1.0 mg/kg.
■ Optimal relaxation occurs once all fasciculations have stopped. 
■ If a repeat dose be required, an anticholinergic agent should be given before the succinylcholine, 
to reduce the potential for asystole.
■ Contraindicated in conditions with neurological deficit, malignant hyperthermia, hyperkalaemia, 
burns, atypical pseudocholinesterase, or cholinesterase inhibition.
Anticholinergic Agents
■ Atropine in a dose of 0.3 – 0.6 mg iv. or glycopyrrolate 0.2 – 0.4 mg iv. may be used to decrease the 
bradycardia associated with the stimulus.
■ Anticholinergic agents should be administered intravenously in sufficient time (1 – 3 minutes) 
before the stimulus to attenuate the vagal effects on the heart.
■ They are recommended during the first treatment where the incidence of subconvulsive stimuli is 
higher while the convulsive threshold is evaluated.
■ Glycopyrrolate may be a preferable drug in the elderly, since it is less likely to cause tachycardia 
and has a reduced incidence of postictal delirium compared to atropine.
130 C H A P T E R 9E L E C T R O CO N V U L S I V E T H E R A P Y G U I D E L I N E S
Post-Anesthetic Period
■ Communicate any medical or anesthetic concerns to the recovery area nurse.
■ Ensure the patient’s airway, breathing, and circulation continues to remain stable, and administer
supplemental oxygenation if required.
■ Remain in the recovery area to receive the initial set of vital signs from the PAR nurse, including
• Respiratory rate.
• Pulse rate and rhythm.
• Blood pressure.
• Oxygen saturation.
• Level of consciousness.
■ Chart and sign anesthetic drugs and dosages PAR, noting comments regarding any complications 
and/or suggestions for changes for future ECT sessions on the anesthesia record.
■ Either discard contaminated needles, syringes, and airway equipment in the appropriate 
containers, or send them to CSD for cleaning.
■ Diagnose and treat abnormalities in vital signs and other complications, including, but 
not limited to
• Postictal delirium.
• Headache.
• Nausea and vomiting.
• Bronchospasm.
• Angina.
• Hypo/hyperglycemia in diabetic patients.
■ Note serious complications in the chart and/or communicate them to the patient’s physician.
The patient's medical condition is the anesthetist’s responsibility until the patient is discharged 
from the PAR. Discharge from the PAR is a responsibility of the anesthetist, delegated to the PAR 
nurses who use established discharge criteria according to the “ECT Nursing Record.” To be 
discharged from the PAR, the patient must be free of complications and have his or her vital 
signs returned to baseline.
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Chapter 10
TRAINING AND PRIVILEGING FOR HEALTH CARE PROFESSIONALS
Introduction
The goal of training and privileging systems is to ensure
that practitioners possess the knowledge and skills required to
provide safe and effective treatment. This is even more impor-
tant in the case of ECT, given the controversy and negative per-
ceptions that surround ECT. 
It is the responsibility of the authority providing the ECT
service (usually a health authority) to ensure that professionals
who provide the services have the necessary knowledge, skills
and attitudes to provide safe and effective treatment in an envi-
ronment that is empathetic to the needs of patients and their
significant others. “Privileging” is the process where the chief of
psychiatry or medicine assesses the knowledge and skills of a
medical practitioner who wishes to be involved with the ECT
treatment team, and decides to grant that privilege to the prac-
titioner. A similar process should occur with nurses involved in
ECT, where the director of nursing or other nursing authority
ensures that the nurses working in the ECT service have the
necessary knowledge, skills and attitudes, although this may
not be formally known as “privileging”.
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Introduction, continued
In addition to professionals involved in direct administration of ECT who should go through a
formal privileging system or its equivalent, a number of others need competence in aspects of ECT.
For example, psychiatrists or general practitioners who prescribe ECT but do not provide it, and
nurses on units where people receive ECT, need considerable knowledge about its indications, effects,
side effects, patient education issues, and the like. While the health authority does not need a special
ECT privileging system for these people, it does have a responsibility to ensure that professionals are
competent and keep up with developments in the field.
Privileging and training are closely linked. Basic training is received before entering practice
and subsequently is the basis for developing and maintaining the knowledge, skills, and attitudes
that privileging requires. While the health authority is not responsible for preparing students in
nursing and psychiatry, their feedback to professional schools in areas such as the delivery of ECT
may be helpful for preparing students. In addition, health authorities along with the professions
have a responsibility for ensuring that practitioners keep up-to-date on developments in ECT. This
chapter includes lists of the knowledge and skills that should be considered in establishing privileg-
ing criteria for ECT.
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Competencies Required
ECT has evolved into a complex medical procedure that requires interaction among many
health care providers. To accomplish the successful outcome of electroconvulsive therapy, it is 
necessary for entire teams to stay abreast of the advances in the practice of ECT. This includes refer-
ring physicians, attending nurses, and staff of the ECT service, including staff in the receiving area, 
treatment area, post-operative recovery area, and the outpatient post-discharge area. Staff should 
be trained in the historic aspects of ECT as well as advances in technique, including stimulus dosing,
electrode placement choices, physiological modifications of induced seizures, and physiological 
monitoring during ECT and in the recovery area, as well as post-ECT care on the ward or in 
outpatient clinics.
Physicians who do ECT need to have mastered the following knowledge levels or compentencies
■ Indications for the use of ECT.
■ Risk-benefit assessments.
■ Patient selection and evaluation.
■ Consent procedures for both voluntary and involuntary patients.
■ Preparation of patients.
■ Types and use of ECT equipment.
■ Techniques of ECT administration.
■ Anesthetics and muscle relaxants.
■ Airway management and oxygenation.
■ Bite-blocks and nerve stimulators.
■ Electrode  placement.
■ Stimulus parameters and dosing, including the concept of threshold.
■ Monitoring of EEG and motor convulsions.
■ Electrophysiological monitoring of heart rhythms and blood pressure.
■ Management of missed and prolonged seizures.
■ The concept of inadequate seizure.
■ Emergency use of ECT.
■ Management of medical emergencies during ECT.
■ Documentation of inter-ECT interval progress.
■ Evaluation of therapeutic outcomes and side effects, in particular, cognition. 
■ The use of maintenance ECT.
■ Post-ECT medication management, particularly to prevent relapse and recurrence.
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Competencies Required, continued
Family physicians and psychiatrists referring patients for treatment need to know
■ Indications for the use of ECT.
■ Risk benefit assessments.
■ Patient selection and evaluation.
■ Consent procedures for both voluntary and involuntary patients.
■ Documentation of inter ECT interval progress.
■ Evaluation of therapeutic outcomes and side effects, in particular cognition.
■ Post-ECT medication management, particularly to prevent relapse and recurrence.
To address recruitment and continuing education issues in remote or rural hospitals, a cus-
tomized locaL continuing education program for interested physicians should be considered. The
continuing education course should not only bring the knowledge and practice to contemporary
standards, but should help form linkages with major teaching hospitals. Policies should be developed
to refer patients to teaching hospitals if problems are encountered in the treatment process.
Continuing education programs should include both didactic lecture or seminar components
and practical hands-on training with a mentor.
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The head of the department of psychiatry (or equivalent) should be responsible for privileging 
functions, including appointments, re-appointments, monitoring, performance appraisals, and 
recommendations for privileges to practice ECT. Privileges for ECT practice should be reviewed 
every second year.
It is recommended that privileges for the administration of ECT should be restricted to Royal
College certified psychiatrists trained in ECT practice, whenever possible. Where trained psychia-
trists are not available, another physician with an interest in psychiatry could be specifically
trained in the modern practice of ECT to meet regional needs. In situations where the treating practi-
tioner is a trained physician other than a psychiatrist, a mandatory psychiatric consultation should
be required for every patient before ECT commences.
In determining whether a psychiatrist should be privileged for the ECT service the person
responsible should use as a basis this Guideline including skills and knowledge outlined in this chap-
ter, although it is difficult to get an agreement about what constitutes a basic minimum require-
ment for the practice of ECT and for the maintenance of competence. It is, however, recommended,
that ECT practitioners must keep up with developments in the field in terms of research, advances in
technique, and evolving indications for the use of ECT, as well as maintaining an active ECT practice
on an bi-annual basis.
Privileging Physicians
137 C H A P T E R 10E L E C T R O CO N V U L S I V E T H E R A P Y G U I D E L I N E S
TRAINING AND PRIVILEGING FOR HEALTH CARE PROFESSIONALSC H A P T E R  I 0
TRAINING AND PRIVILEGING FOR HEALTH CARE PROFESSIONALSC H A P T E R  I 0
Training Nurses
General Nursing Staff
Nursing orientation should include an overview of ECT, including its history, indications, and poten-
tial risks.
Nursing Staff Working in Psychiatry and in Treatment Areas and Recovery Rooms
Nursing orientation in Psychiatry should include
■ The history of ECT.
■ Indications for and potential risks of ECT.
■ Pre-ECT evaluation and medical review.
■ Informed consent procedures.
■ ECT technique.
■ Information to be included in patient and family education.
In addition, nursing staff working in treatment areas and recovery rooms should have orientation,
which includes nursing participation in ECT treatment and post-anesthetic recovery (including 
management of emergency situations).
Ensuring Qualified Nursing Support
Management for mental health acute care services within health authorities should ensure job
descriptions and qualifications, hiring processes and orientation are developed to ensure effective
and supportive nursing care for patients receiving ECT services (see Chapter 8, “Nursing considera-
tions”). Nurses require ongoing orientation sufficient to provide care that is based on current best
evidence. Program and individual evaluations are provided to support nurses to achieve nursing
practice standards and to implement changes when required.
Nurses play an important role in the delivery of electroconvulsive therapy, from patient 
and family education and preparation before treatment to follow-up and support for patients and
family after treatment is given. Education about ECT needs to be included as part of basic nursing
education. For those nurses entering the field of psychiatry, more extensive education needs to be
provided. The following recommendations for training and orientation are intended to provide
guidelines for schools of nursing and for hospitals providing psychiatric treatment.
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Health Authority
Appointing Nurses
TRAINING AND PRIVILEGING FOR HEALTH CARE PROFESSIONALSC H A P T E R  I 0
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Chapter 11
Q UA L I T Y  A S S E S S M E N T
It is recommended that each hospital providing ECT
appoint an ECT Director to oversee the effective provision of 
ECT at that hospital, including
■ the availability of patient and family education materials
■ appropriate clinical care of patients
■ monitoring of ECT as a therapy
■ privileging of physicians to perform ECT.
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QUALITY ASSESSMENTC H A P T E R  1 1
Program Quality Improvement (QI Initiatives)
The purpose of quality assurance or improvement programs is to improve outcomes. It is only by
critically looking at our work that we may objectively identify areas for possible improvements.
Improved outcomes include
■ Better staff training.
■ Better information being received by patients, families, and other decision-makers.
■ Reduction in side effects.
■ Improved patient satisfaction.
■ Improved patient outcomes regarding symptom reduction.
Monitoring of ECT should be the responsibility of the health authority, through quality improvement
initiatives defined by designated psychiatric quality improvement teams. The 
following are recommendations for activities for quality assurance and/or improvement.
■ As part of a QI process, an annual review should include one or more of the following
• Documented consent.
• Pre-ECT checklists.
• ECT treatment forms.
• Side effects and complications.
• Basic treatment outcomes.
• Patient and family education activities.
■ A review of nursing and physician training, as well as privileging of ECT, should occur every 
second year.
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Information to Be Kept by Health Authorities (HA)
The following information is considered essential for HAs to maintain, in order to understand 
their own appropriate use of ECT as a therapy, and for potential inter-hospital comparisons by 
the Ministry of Health Services. There should be a record of the following variables for each 
individual patient
■ Age.
■ Sex.
■ Personal Health Number.
■ Whether this is an index course or maintenance course of ECT.
■ Whether this is an inpatient or outpatient.
■ Dates of treatment.
■ Names of the attending physicians and their professional degrees (family physicians 
or psychiatrists).
■ Any side effects or complications that occurred during the course of ECT.
■ The primary diagnosis as a reason for requiring ECT.
■ The indications for ECT.
■ A statement about previous ECT response.
■ Whether the patient was voluntary or involuntary.
■ Elements of pre-ECT workup completed.
■ Basic outcome measures, including a cognitive scale, the clinical Global Impression Scale, 
a depression scale, and a patient satisfaction measure (qualitative or quantitative).
■ The reason ECT is stopped.
■ The number of unilateral and bilateral treatments.
■ Treatment location (name of hospital).
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Appendices A–D at the end of this chapter show sample forms and slightly-revised checklists from
the UBC Mood Disorders Centre for index and maintenance courses of ECT.
Having maintained these individual records, Health Authorities should be able to collate the 
following data for inter-unit and inter-regional comparisons when required
■ The number of inpatients and outpatients per year having an index course of ECT.
■ The number of patients having maintenance ECT each year on an inpatient or outpatient basis.
■ The age range and distribution of ECT treatment by sex.
■ The average number of treatments for an index episode.
■ The average number of treatments per year, per person, for maintenance ECT.
■ A list of the primary diagnosis of the patients undergoing ECT.
■ A list of complications related to ECT.
■ Basic outcome measures.
■ Reasons for stopping ECT.
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Information to Be Kept by Health Authorities (HA), continued
Sample Form for Index Course of ECT
NAME:________________________________  SEX:______
DOB:________________PHN:________________________
HOSPITAL________________________________________
INDIVIDUAL ECT RECORD: INDEX COURSE: COMPLETED ON DISCHARGE
Inpatient  ■ or    Outpatient  ■
Dates of Treatments:                    (+ Bil/Uni) Dates of Treatments:                      (+ Bil/Uni)
1.______________________   ________    9._______________________   ________
2.______________________   ________ 10.______________________   ________
3.______________________   ________ 11.______________________   ________
4.______________________   ________ 12.______________________   ________
5.______________________   ________ 13.______________________   ________
6.______________________   ________ 14.______________________   ________
7.______________________   ________ 15.______________________   ________
8.______________________   ________              Total Unilateral_______  Total Bilateral_______
Name of Physicians Monitoring Effects of ECT Professional Degree (Family Phys./Psych.)
(Attending)
____________________________________                 _________________________________
____________________________________                 _________________________________
____________________________________                 _________________________________
Adverse Reactions and Complications:
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_____
REASON ECT STOPPED: ■  Maximum benefit      ■  Adverse effects      ■  Limited or no response
From UBC Mood Disorders Centre. Used with permission.
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Sample Checklist, Index Course
NAME:________________________________  SEX:______
DOB:________________PHN:________________________
HOSPITAL________________________________________
UBC MOOD DISORDERS ECT CHECKLIST (Revised)
PRIMARY DIAGNOSIS: INDICATIONS FOR ECT: (check all that apply)
■  Major Depressive Disorder ■  Rapid response needed
■  Bipolar Disorder, Depressed ■  Acute suicidality
■  Bipolar Disorder, Manic ■  Physical deterioration
■  Schizophrenia ■  Refractory to medications
■  Schizoaffective Disorder ■  Other (please specify):
■  Parkinson’s Disease
■  Other (please specify):
PREVIOUS ECT RESPONSE:     ■  Not applicable   ■  Good response   ■  Limited or no response
PATIENT: ■  Voluntary ➡➡ ■  Risks/benefits explained    ➡ ■  Patient consent signed
STATUS:      ■  Involuntary   ➡➡ ■  Second opinion completed  ➡ ■  Medical director consent
signed (± patient consent)
PRE-ECT WORKUP:      ■  Physical Examination ■  Lab ■  ECG (if necessary)
■  Anaesthesia consult ■  ECT orders written
OUTCOME MEASURES  PRE-ECT    POST-ECT (at discharge or one week post-
discharge, or 15 treatments of maintenance)
Clinical Global Impression ■ Not at all ill
■ Borderline ill
■ Mildly ill
■ Moderately ill
■ Markedly ill
■ Severely ill
■ Extremely ill
Hamilton Depression Rating 
Scale (optional)
17-item
7-item
24-item total
Beck Depression Inventory 
(optional)
Geriatric Depression Scale
or Other Depression Scale
From UBC Mood Disorders Centre. Used with permission.
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■ Very much improved
■ Much improved
■ Minimally improved
■ Not improved
■ Worse
Sample Form for Maintenance Course of ECT
NAME:___________________________________  SEX:______
DOB:_________________PHN:__________________________
HOSPITAL___________________________________________
INDIVIDUAL ECT RECORD: MAINTENANCE COURSE
Inpatient  ■ or    Outpatient  ■
Dates of Treatments:              (+ Bil/Uni) Dates of Treatments:                 (+ Bil/Uni)
1.______________________   ________    9.______________________   ________
2.______________________   ________ 10.______________________   ________
3.______________________   ________ 11.______________________   ________
4.______________________   ________ 12.______________________   ________
5.______________________   ________ 13.______________________   ________
6.______________________   ________ 14.______________________   ________
7.______________________   ________ 15.______________________   ________
8.______________________   ________              Total Unilateral_______    Total Bilateral_______
Name of Physicians Monitoring Effects of ECT Professional Degree (Family Phys./Psych.)
(Attending)
____________________________________                 _________________________________
____________________________________                 _________________________________
____________________________________                 _________________________________
Adverse Reactions and Complications:
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
_________________________________________________________________________________________
From UBC Mood Disorders Centre. Used with permission.
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Sample Checklist, Maintenance Course
NAME:______________________________  SEX:______
DOB:________________PHN:______________________
HOSPITAL______________________________________
UBC MOOD DISORDERS ECT CHECKLIST (Revised)
PRIMARY DIAGNOSIS: INDICATIONS FOR ECT: (check all that apply)
■  Major Depressive Disorder ■  Past failure on medications
■  Bipolar Disorder, Depressed ■  Past history of response to maintenance ECT
■  Bipolar Disorder, Manic ■  Other (please specify):
■  Schizophrenia
■  Schizoaffective Disorder
■  Parkinson’s Disease
■  Other (please specify):
PREVIOUS ECT RESPONSE:     ■  Not applicable   ■  Good response   ■  Limited or no response
PATIENT: ■  Voluntary ➡➡ ■  Risks/benefits explained    ➡ ■  Patient consent signed
STATUS:      ■  Involuntary   ➡➡ ■  Second opinion completed  ➡ ■  Medical director consent
signed (± patient consent)
OUTCOME MEASURES  PRE-ECT    POST-ECT (at time of new consent for 
maintenance, either 6 months or 15 treatments)
Folstein Mini-Mental State Exam
Clinical Global Impression ■ Not at all ill
■ Borderline ill
■ Mildly ill
■ Moderately ill
■ Markedly ill
■ Severely ill
■ Extremely ill
Hamilton Depression Rating 
Scale (optional)
17-item
7-item
24-item total
Beck Depression Inventory 
(optional)
Geriatric Depression Scale
or Other Depression Scale
From UBC Mood Disorders Centre. Used with permission.
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■ Very much improved
■ Much improved
■ Minimally improved
■ Not improved
■ Worse
FEEDBACK FORM
Feedback: Electroconvulsive Therapy
Guidelines for Health Authorities 
in British Columbia.
August 2002
The Electroconvulsive Therapy: Guidelines for Health Authorities in
British Columbia document will be periodically updated. To assist in 
this process, please answer any or all of the following questions and
send it to the address shown at the bottom of this form.
Thank you for your assistance.
1. Is this a useful document? Will it assist you in planning, 
delivering and evaluating Electroconvulsive Therapy in your 
region  Briefly explain your response.
2. Please identify errors and identify any additional issues you
would suggest for the next edition.
3. Does the document as a whole provide clear and appropriate 
guidelines for developing or improving ECT services?
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FEEDBACK FORMC H A P T E R  I
Feedback: Electroconvulsive Therapy
4. Are the suggestions for data elements to be kept for Quality 
Improvement (QI) Purposes (on page?) complete? Do you have any 
concerns about  being able to collect and analyse this data?
5. Additional comments: (Please attach another page if you 
need more space.)
Name  
Position
Health Authority
Address
Phone
Fax
E-Mail
Please return to: Mental Health and Addictions, Ministry of Health
Services, 1515 Blanshard Street, Victoria, BC V8W 3C8
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Mental Health 
Evaluation & Community 
Consultation Unit
2250 Wesbrook Mall,
Vancouver, BC  V6T 1W6
www.mheccu.ubc.ca
